BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplan MM, Gershwin ME. Primary Biliary Cirrhosis. N Engl J Med 2005;353:1261-73. [DOI: 10.1056/nejmra043898] [Cited by in Crossref: 942] [Cited by in F6Publishing: 1001] [Article Influence: 52.3] [Reference Citation Analysis]
Number Citing Articles
1 Kalashnikov M, Akulkina L, Brovko M, Sholomova V, Yanakaeva A, Abdurakhmanov D, Moiseev S. Interstitial Lung Disease in Primary Biliary Cholangitis: A Cohort Prospective Study. Life 2023;13:416. [DOI: 10.3390/life13020416] [Reference Citation Analysis]
2 Kowdley KV, Bowlus CL, Levy C, Mayo MJ, Pratt DS, Vuppalanchi R, Younossi ZM. Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis. Am J Gastroenterol 2023;118:232-42. [PMID: 36729104 DOI: 10.14309/ajg.0000000000002070] [Reference Citation Analysis]
3 de Veer RC, van Hooff MC, da Silva G, Harms MH, Metselaar HJ, Willemse J, Utomo E, van der Meer AJ. Quality of life in Dutch patients with primary biliary cholangitis: Discrepancies between patients' perspectives and objective disease parameters. Hepatol Res 2023. [PMID: 36635224 DOI: 10.1111/hepr.13880] [Reference Citation Analysis]
4 Betterle C, Furmaniak J, Sabbadin C, Scaroni C, Presotto F. Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy. J Endocrinol Invest 2023. [PMID: 36609775 DOI: 10.1007/s40618-022-01994-1] [Reference Citation Analysis]
5 Morgan MA, Sundaram KM. Primary biliary cholangitis: review for radiologists. Abdom Radiol (NY) 2023;48:127-35. [PMID: 34743232 DOI: 10.1007/s00261-021-03335-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 de Veer RC, van Hooff MC, Corpechot C, Thorburn D, Invernizzi P, Lammers WJ, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Parés A, Mason AL, Kowdley KV, Trivedi PJ, Hirschfield GM, Goet JC, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Hansen BE, Harms MH, van der Meer AJ. Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis. Am J Gastroenterol 2022. [PMID: 36621963 DOI: 10.14309/ajg.0000000000002128] [Reference Citation Analysis]
7 Sato T, Kumagai I, Suzuki K, Kakisaka K, Abe K. Over 3-Years Follow-Up of a Case of Primary Biliary Cholangitis With Autoimmune Hyperthyroidism: Factors Associated With Liver Dysfunction. Cureus 2022;14:e32941. [PMID: 36712741 DOI: 10.7759/cureus.32941] [Reference Citation Analysis]
8 Kruk B, Milkiewicz M, Raszeja-Wyszomirska J, Milkiewicz P, Krawczyk M. A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients. Orphanet J Rare Dis 2022;17:419. [PMID: 36397154 DOI: 10.1186/s13023-022-02565-6] [Reference Citation Analysis]
9 de Veer RC, Harms MH, Corpechot C, Thorburn D, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Parés A, Mason AL, Kowdley KV, Trivedi PJ, Hirschfield GM, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lammers WJ, Hansen BE, van Buuren HR, van der Meer AJ; Global PBC Study Group. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid. Aliment Pharmacol Ther 2022;56:1408-18. [PMID: 36138566 DOI: 10.1111/apt.17226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shaker M, Mansour N, John BV. Primary Biliary Cholangitis in Males: Pathogenesis, Clinical Presentation, and Prognosis. Clin Liver Dis 2022;26:643-55. [PMID: 36270721 DOI: 10.1016/j.cld.2022.06.008] [Reference Citation Analysis]
11 Chen R, Tang R, Ma X, Gershwin ME. Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis. Clin Liver Dis 2022;26:583-611. [PMID: 36270718 DOI: 10.1016/j.cld.2022.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hitomi Y, Aiba Y, Ueno K, Nishida N, Kawai Y, Kawashima M, Tsuiji M, Iwabuchi C, Takada S, Miyake N, Nagasaki M, Tokunaga K, Nakamura M. rs2013278 in the multiple immunological-trait susceptibility locus CD28 regulates the production of non-functional splicing isoforms. Hum Genomics 2022;16:46. [PMID: 36271469 DOI: 10.1186/s40246-022-00419-7] [Reference Citation Analysis]
13 Vílchez-oya F, Balastegui Martin H, García-martínez E, Corominas H. Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjögren’s syndrome: A critical review. Front Immunol 2022;13:1003054. [DOI: 10.3389/fimmu.2022.1003054] [Reference Citation Analysis]
14 Trevisani VFM, Pinheiro AC, de Magalhães Souza Fialho SC, Fernandes MLMS, Pugliesi A, Pasoto SG, Lopes MLL, Guedes LKN, Miyamoto ST, Dos Santos LC, Appenzeller S, Fidelix T, Ribeiro SLE, de Brito DCSE, Libório-Kimura TN, Santos MCLFS, Cantali DU, Gennari JD', Capobianco KG, Civile VT, Pinto ACPN, da Rocha AP, Rocha-Filho CR, Oliveira FR, Valim V. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sjögren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian society of rheumatology (hepatic, gastrointestinal and pancreatic). Adv Rheumatol 2022;62:35. [PMID: 36217186 DOI: 10.1186/s42358-022-00267-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang Q, Wang Y, Qiao W, Xu B, Liu Y, Zhang X, Li W, Zhao J, Liu M, Zhang Y, Chen D, Huang C, Jin R. The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism. Front Immunol 2022;13:995223. [DOI: 10.3389/fimmu.2022.995223] [Reference Citation Analysis]
16 Floreani A, Scaffidi M, Coco B, Giannini EG, Labanca S, Bonaiuto E, De Martin S, Invernizzi P, Carbone M, Alvaro D, Bragazzi MC, Calvaruso V, Cossiga V, Cazzagon N; Italian Foundation for Research in Hepatology (FIRE). Primary biliary cholangitis: perception and expectation of illness. Dig Liver Dis 2022;54:1230-3. [PMID: 35277351 DOI: 10.1016/j.dld.2022.02.006] [Reference Citation Analysis]
17 Syed H, Penner T, Mason AL. Linking Human Betaretrovirus with Autoimmunity and Liver Disease in Patients with Primary Biliary Cholangitis. Viruses 2022;14:1941. [DOI: 10.3390/v14091941] [Reference Citation Analysis]
18 Wu Y, Fan X, Yu H, Liu J, Duan Y, Zhang S, Yan L, Du Y, Liu H. Macrophage polarization is involved in liver fibrosis induced by β-adrenoceptor autoantibody. Acta Biochim Biophys Sin (Shanghai) 2022. [PMID: 35983976 DOI: 10.3724/abbs.2022102] [Reference Citation Analysis]
19 Saeki C, Oikawa T, Ueda K, Nakano M, Torisu Y, Saruta M, Tsubota A. Serum Insulin-Like Growth Factor 1 Levels, Facture Risk Assessment Tool Scores and Bone Disorders in Patients with Primary Biliary Cholangitis. Diagnostics 2022;12:1957. [DOI: 10.3390/diagnostics12081957] [Reference Citation Analysis]
20 Er C, Dyson J, Jones D, Sayer J. Primary biliary cholangitis presenting with Fanconi syndrome: an important phenotype. BMJ Case Rep 2022;15:e248461. [DOI: 10.1136/bcr-2021-248461] [Reference Citation Analysis]
21 Walsh K, Park J. Far From the Biliary Tree: A Case of Overlapping Autoimmune Liver Disease in a Patient Presenting With Sicca Symptoms. Cureus 2022. [DOI: 10.7759/cureus.26760] [Reference Citation Analysis]
22 Nguyen HH, Fritzler MJ, Swain MG. A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes. Front Mol Med 2022;2. [DOI: 10.3389/fmmed.2022.914505] [Reference Citation Analysis]
23 Hong YM, Yoon KT, Cho M. Primary Biliary Cholangitis with Ankylosing Spondylitis. Korean J Gastroenterol 2022;79:270-273. [DOI: 10.4166/kjg.2022.048] [Reference Citation Analysis]
24 Ikami Y, Izumi D, Hasegawa Y, Suzuki N, Sakaguchi Y, Hakamata T, Otsuki S, Yagihara N, Iijima K, Kashimura T, Chinushi M, Minamino T, Inomata T. The Risk of Ventricular Tachyarrhythmias in Patients with Antimitochondrial Antibodies-Related Noncardiac Diseases. Int Heart J 2022;63:476-85. [PMID: 35650149 DOI: 10.1536/ihj.22-075] [Reference Citation Analysis]
25 Martínez-garcía J, Molina A, González-aseguinolaza G, Weber ND, Smerdou C. Gene Therapy for Acquired and Genetic Cholestasis. Biomedicines 2022;10:1238. [DOI: 10.3390/biomedicines10061238] [Reference Citation Analysis]
26 Kouno T, Liu X, Zhao H, Kisseleva T, Cable EE, Schnabl B. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. J Biol Chem 2022;298:102056. [PMID: 35605662 DOI: 10.1016/j.jbc.2022.102056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Xie M, Nyabanga CT, Sehmbhi M, Khalili NA, Chon C, Kamath A, Dinani AM, Weisberg IS. Clinicopathological and Imaging Features of Primary Biliary Cholangitis.. [DOI: 10.1101/2022.04.29.22274511] [Reference Citation Analysis]
28 Abenavoli L, Procopio AC, Cinaglia P, Zanza C, Grazie CD, Longhitano Y, Libicherova P, Luzza F. Clinical Patterns of Primary Biliary Cholangitis: Comparison Between Two European Case Series. Rev Recent Clin Trials 2022;17:136-42. [PMID: 35718979 DOI: 10.2174/1574887117666220617095856] [Reference Citation Analysis]
29 Aubin A, Lombard-vadnais F, Collin R, Aliesky HA, Mclachlan SM, Lesage S. The NOD Mouse Beyond Autoimmune Diabetes. Front Immunol 2022;13:874769. [DOI: 10.3389/fimmu.2022.874769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Cariello M, Gadaleta RM, Moschetta A. The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment. Curr Opin Gastroenterol 2022;38:136-43. [PMID: 35034082 DOI: 10.1097/MOG.0000000000000807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
31 Trussoni CE, O'Hara SP, LaRusso NF. Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target. Semin Immunopathol 2022. [PMID: 35178659 DOI: 10.1007/s00281-022-00909-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Yang Y, Choi J, Chen Y, Invernizzi P, Yang G, Zhang W, Shao TH, Jordan F, Nemeria NS, Coppel RL, Ridgway WM, Kurth M, Ansari AA, Leung PSC, Gershwin ME. E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants. Hepatology 2022;75:266-79. [PMID: 34608663 DOI: 10.1002/hep.32172] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
33 Shamshtein D, Liwinski T. Pathogenesis and management of fatigue in primary biliary cholangitis. Fatigue: Biomedicine, Health & Behavior 2022;10:1-25. [DOI: 10.1080/21641846.2022.2034473] [Reference Citation Analysis]
34 Bergasa NV. Primary Biliary Cholangitis. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_3] [Reference Citation Analysis]
35 Colapietro F, Lleo A, Generali E. Antimitochondrial Antibodies: from Bench to Bedside. Clin Rev Allergy Immunol 2022;63:166-77. [PMID: 34586589 DOI: 10.1007/s12016-021-08904-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
36 Kim W. Chronic Liver Disease. Sex/Gender-Specific Medicine in the Gastrointestinal Diseases 2022. [DOI: 10.1007/978-981-19-0120-1_14] [Reference Citation Analysis]
37 Bergasa NV. Complications of Liver Disease. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_15] [Reference Citation Analysis]
38 Patterson JW, Kwock J, Flowers R, Guffey D, Pruitt L, Stowman AM, David BAM. Systemic Disease and the Skin. Atlas of Dermatology, Dermatopathology and Venereology 2022. [DOI: 10.1007/978-3-319-53808-2_48] [Reference Citation Analysis]
39 Yang J, Sontag D, Kung S, Minuk GY. Fibroblast Growth Factor 19 Induced Changes in Non-malignant Cholangiocytes. J Clin Transl Hepatol 2021;9:909-16. [PMID: 34966654 DOI: 10.14218/JCTH.2021.00087] [Reference Citation Analysis]
40 de Veer RC, da Silva G, van Hooff MC, Harms MH, Metselaar HJ, Willemse J, Utomo E, van der Meer AJ. Measurement properties of the PBC-40 and PBC-27: a Dutch validation study. BMJ Open Gastroenterol 2021;8:e000758. [PMID: 34916226 DOI: 10.1136/bmjgast-2021-000758] [Reference Citation Analysis]
41 Hitomi Y, Aiba Y, Ueno K, Nishida N, Kawai Y, Kawashima M, Yasunami M, Gervais O, Ito M, Cordell HJ, Mells GF, Nagasaki M, Tokunaga K, Tsuiji M, Nakamura M. rs9459874 and rs1012656 in CCR6/FGFR1OP confer susceptibility to primary biliary cholangitis. J Autoimmun 2022;126:102775. [PMID: 34864633 DOI: 10.1016/j.jaut.2021.102775] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Kilanczyk E, Banales JM, Jurewicz E, Milkiewicz P, Milkiewicz M. p-STAT3 is a PDC-E2 interacting partner in human cholangiocytes and hepatocytes with potential pathobiological implications. Sci Rep 2021;11:21649. [PMID: 34737337 DOI: 10.1038/s41598-021-01060-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Vogt S, Mattner J. NKT Cells Contribute to the Control of Microbial Infections. Front Cell Infect Microbiol 2021;11:718350. [PMID: 34595131 DOI: 10.3389/fcimb.2021.718350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
44 Yehezkel E, Israel I, Houri I, Leshno M, Shibolet O, Zigmond E. Real-World Management of Patients with Primary Biliary Cholangitis-A Retrospective Study from a Tertiary Medical Center in Israel. J Clin Med 2021;10:4551. [PMID: 34640567 DOI: 10.3390/jcm10194551] [Reference Citation Analysis]
45 Costa V, Moreira M, Costa R, Fontes J. Primary Biliary Cholangitis Overlap With Autoimmune Hepatitis? A Case Report. J Med Cases 2021;12:131-3. [PMID: 34434444 DOI: 10.14740/jmc3623] [Reference Citation Analysis]
46 Zhou QY, Zhou WX, Sun XY, Wu B, Zheng WY, Li Y, Qian JM. Autoimmune enteropathy and primary biliary cholangitis after proctocolectomy for ulcerative colitis: A case report and review of the literature. World J Gastroenterol 2021; 27(29): 4929-4938 [PMID: 34447236 DOI: 10.3748/wjg.v27.i29.4929] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Guatibonza-García V, Gaete PV, Pérez-Londoño A, Puerto-Baracaldo DK, Gutiérrez-Romero SA, Mendivil CO, Tapias M. Poor performance of anti-mitochondrial antibodies for the diagnosis of primary biliary cholangitis in female Colombian patients: A single-center study. World J Gastroenterol 2021; 27(29): 4890-4899 [PMID: 34447233 DOI: 10.3748/wjg.v27.i29.4890] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Itoh A, Adams D, Huang W, Wu Y, Kachapati K, Bednar KJ, Leung PSC, Zhang W, Flavell RA, Gershwin ME, Ridgway WM. Enoxacin Up-Regulates MicroRNA Biogenesis and Down-Regulates Cytotoxic CD8 T-Cell Function in Autoimmune Cholangitis. Hepatology 2021;74:835-46. [PMID: 33462854 DOI: 10.1002/hep.31724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
49 Goet JC, Murillo Perez CF, Harms MH, Floreani A, Cazzagon N, Bruns T, Prechter F, Dalekos GN, Verhelst X, Gatselis NK, Lindor KD, Lammers WJ, Gulamhusein A, Reig A, Carbone M, Nevens F, Hirschfield GM, van der Meer AJ, van Buuren HR, Hansen BE, Parés A; GLOBAL PBC Study Group. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. Am J Gastroenterol 2021;116:1514-22. [PMID: 33941746 DOI: 10.14309/ajg.0000000000001285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
51 Gordon SC, Trudeau S, Regev A, Uhas JM, Chakladar S, Pinto-Correia A, Gottlieb K, Schlichting D. Baricitinib and primary biliary cholangitis. J Transl Autoimmun 2021;4:100107. [PMID: 34195587 DOI: 10.1016/j.jtauto.2021.100107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
52 Sasaki M, Sato Y, Nakanuma Y. Interferon-induced protein with tetratricopeptide repeats 3 may be a key factor in primary biliary cholangitis. Sci Rep 2021;11:11413. [PMID: 34075171 DOI: 10.1038/s41598-021-91016-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, Jones DE, Nakamura M, Ueno K, Hitomi Y, Kawashima M, Nishida N, Tokunaga K, Nagasaki M, Tanaka A, Tang R, Li Z, Shi Y, Liu X, Xiong M, Hirschfield G, Siminovitch KA, Carbone M, Cardamone G, Duga S, Gershwin ME, Seldin MF, Invernizzi P; Canadian-US PBC Consortium, Italian PBC Genetics Study Group, UK-PBC Consortium, Japan PBC-GWAS Consortium. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology 2021;160:2483-2495.e26. [PMID: 33675743 DOI: 10.1053/j.gastro.2021.02.061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
54 Mulinacci G, Palermo A, Invernizzi P, Carbone M. Old and novel prognostic biomarkers in primary biliary cholangitis. Expert Opinion on Orphan Drugs 2021;9:123-31. [DOI: 10.1080/21678707.2021.1927700] [Reference Citation Analysis]
55 Wu H, Chen C, Ziani S, Nelson LJ, Ávila MA, Nevzorova YA, Cubero FJ. Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells 2021;10:1107. [PMID: 34062960 DOI: 10.3390/cells10051107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
56 Adejumo AC, Akhtar DH, Dennis BB, Cholankeril G, Alayo Q, Ogundipe OA, Kim D, Ahmed A. Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA. Dig Dis Sci 2021;66:1461-76. [PMID: 32535779 DOI: 10.1007/s10620-020-06402-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Iljinsky IM, Tsirulnikova OM. Primary biliary cholangitis. RJTAO 2021;23:162-170. [DOI: 10.15825/1995-1191-2021-1-162-170] [Reference Citation Analysis]
58 Gijbels E, Pieters A, De Muynck K, Vinken M, Devisscher L. Rodent models of cholestatic liver disease: A practical guide for translational research. Liver Int 2021;41:656-82. [PMID: 33486884 DOI: 10.1111/liv.14800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
59 Cazzagon N, Floreani A. Primary biliary cholangitis: treatment. Curr Opin Gastroenterol 2021;37:99-104. [PMID: 33492001 DOI: 10.1097/MOG.0000000000000708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
60 Hitomi Y, Aiba Y, Kawai Y, Kojima K, Ueno K, Nishida N, Kawashima M, Gervais O, Khor SS, Nagasaki M, Tokunaga K, Nakamura M, Tsuiji M. rs1944919 on chromosome 11q23.1 and its effector genes COLCA1/COLCA2 confer susceptibility to primary biliary cholangitis. Sci Rep 2021;11:4557. [PMID: 33633225 DOI: 10.1038/s41598-021-84042-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Koyama M, Yamazaki T, Joshita S, Ito A, Ono K, Watanabe T, Yamashita Y, Sugiura A, Kobayashi M, Sato Y, Takahashi M, Okamoto H, Umemura T. An Autopsy Case of Primary Biliary Cholangitis with Histological Submassive Hepatic Necrosis Caused by Acute Hepatitis E Virus Infection. Intern Med 2021;60:1863-70. [PMID: 33518570 DOI: 10.2169/internalmedicine.6337-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 de Vries E, Bolier R, Goet J, Parés A, Verbeek J, de Vree M, Drenth J, van Erpecum K, van Nieuwkerk K, van der Heide F, Mostafavi N, Helder J, Ponsioen C, Oude Elferink R, van Buuren H, Beuers U; Netherlands Association for the Study of the Liver-Cholestasis Working Group. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology 2021;160:734-743.e6. [PMID: 33031833 DOI: 10.1053/j.gastro.2020.10.001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 24.0] [Reference Citation Analysis]
63 Gerussi A, D'Amato D, Cristoferi L, O'Donnell SE, Carbone M, Invernizzi P. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. Ann Hepatol 2020;19:5-16. [PMID: 31771820 DOI: 10.1016/j.aohep.2019.09.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
64 李 惠. Research Progress of Intestinal Flora and Liver Related Diseases. ACM 2021;11:3185-3190. [DOI: 10.12677/acm.2021.117462] [Reference Citation Analysis]
65 Lefkowitch JH. Biliary Disease. Scheuer's Liver Biopsy Interpretation 2021. [DOI: 10.1016/b978-0-7020-7584-1.00005-x] [Reference Citation Analysis]
66 Kawata K, Joshita S, Shimoda S, Yamashita Y, Yamashita M, Kitsugi K, Takatori S, Ohta K, Ito J, Shimoyama S, Noritake H, Suda T, Harada K. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. Hepatol Res 2021;51:80-9. [PMID: 33080094 DOI: 10.1111/hepr.13584] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Saffioti F, Thorburn D, Pinzani M. Primary Biliary Cholangitis. In Clinical Practice 2021. [DOI: 10.1007/978-3-030-53736-4_27] [Reference Citation Analysis]
68 Kovač J. Non-tumoral Pathology of the Intrahepatic Biliary Tract. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-38983-3_18] [Reference Citation Analysis]
69 Sun K, Ma S, Tian S, Zhang M, Liu Y, Li B, Zhou X, Zheng X, Zhou X, Wang L, Han Y. An enhanced level of LAMP-2A participates in CD4+T cell hyperactivity in patients with primary biliary cholangitis. Ann Transl Med 2021;9:101. [PMID: 33569403 DOI: 10.21037/atm-20-2427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Osman KT, Maselli DB, Idilman IS, Rowan DJ, Viehman JK, Harmsen WS, Harnois DM, Carey EJ, Gossard AA, LaRusso NF, Lindor KD, Venkatesh SK, Eaton JE. Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. J Clin Gastroenterol 2021;55:449-57. [PMID: 32976197 DOI: 10.1097/MCG.0000000000001433] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
71 Henriksson E, Andersen B. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front Endocrinol (Lausanne) 2020;11:601349. [PMID: 33414764 DOI: 10.3389/fendo.2020.601349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
72 Middelhoff J, Scheidbach H, Gastinger I, Meyer F. Präkanzerosen und Malignome des Gastrointestinaltrakts: Geschlechtsspezifische Unterschiede bezüglich Inzidenz, Risikoprofil, operativer Therapie und sozioökonomischen Faktoren. coloproctology 2021;43:284-91. [DOI: 10.1007/s00053-020-00502-4] [Reference Citation Analysis]
73 Feng L, Dong K, Zhang X, Ma B, Chen L, Yang Q, Chen Q, Wen X, Jin Q. Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China. PLoS One 2020;15:e0242164. [PMID: 33180817 DOI: 10.1371/journal.pone.0242164] [Reference Citation Analysis]
74 Takahashi F, Sawada J, Minoshima A, Sakamoto N, Ono T, Akasaka K, Takei H, Nishino I, Hasebe N. Antimitochondrial Antibody-associated Myopathy with Slowly Progressive Cardiac Dysfunction. Intern Med 2021;60:1035-41. [PMID: 33116011 DOI: 10.2169/internalmedicine.5600-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Hayashi M, Abe K, Fujita M, Takahashi A, Sekine H, Ohira H. Association between serum ficolin-1 level and disease progression in primary biliary cholangitis. PLoS One 2020;15:e0238300. [PMID: 32915797 DOI: 10.1371/journal.pone.0238300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
76 Grytczuk A, Bauer A, Gruszewska E, Cylwik B, Chrostek L. Changed Profile of Serum Transferrin Isoforms in Primary Biliary Cholangitis. J Clin Med 2020;9:E2894. [PMID: 32911601 DOI: 10.3390/jcm9092894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Yang H, Yang H, Wang L, Shi H, Liu B, Lin X, Chang Q, Chen JDZ, Duan Z. Transcutaneous Neuromodulation improved inflammation and sympathovagal ratio in patients with primary biliary ssscholangitis and inadequate response to Ursodeoxycholic acid: a pilot study. BMC Complement Med Ther 2020;20:242. [PMID: 32738911 DOI: 10.1186/s12906-020-03036-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
78 Harms MH, de Veer RC, Lammers WJ, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Trivedi PJ, Hirschfield GM, Pares A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Hansen BE, Buuren HRV, van der Meer AJ. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut 2020;69:1502-9. [PMID: 31843787 DOI: 10.1136/gutjnl-2019-319057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
79 Deng C, Li W, Fei Y, Wang L, Chen Y, Zeng X, Zhang F, Li Y. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis. Front Immunol 2020;11:1619. [PMID: 32793241 DOI: 10.3389/fimmu.2020.01619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
80 Joshita S, Yamashita Y, Sugiura A, Uehara T, Usami Y, Yamazaki T, Fujimori N, Matsumoto A, Tanaka E, Umemura T. Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis. J Gastroenterol Hepatol 2020;35:1208-14. [PMID: 31724755 DOI: 10.1111/jgh.14929] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
81 Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol 2020;115:1066-74. [PMID: 32618657 DOI: 10.14309/ajg.0000000000000557] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
82 Golonka RM, San Yeoh B, Li Y, Saha P, Abokor AA, Cheng X, Xiao X, Chandrashekar DS, Varambally S, Gonzalez DJ, Ross AC, Vijay-Kumar M. Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice. Am J Physiol Gastrointest Liver Physiol 2020;318:G955-65. [PMID: 32200644 DOI: 10.1152/ajpgi.00349.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Singh K, Kaur J, Kaur JK, Trehan M. Seronegative Primary Biliary Cholangitis in a Middle Age Male- A Rare Entity. jebmh 2020;7:883-886. [DOI: 10.18410/jebmh/2020/193] [Reference Citation Analysis]
84 Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterol J 2020;8:667-74. [PMID: 32299307 DOI: 10.1177/2050640620919585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
85 Ueno K, Aiba Y, Hitomi Y, Shimoda S, Nakamura H, Gervais O, Kawai Y, Kawashima M, Nishida N, Kohn SS, Kojima K, Katsushima S, Naganuma A, Sugi K, Komatsu T, Mannami T, Matsushita K, Yoshizawa K, Makita F, Nikami T, Nishimura H, Kouno H, Kouno H, Ohta H, Komura T, Tsuruta S, Yamauchi K, Kobata T, Kitasato A, Kuroki T, Abiru S, Nagaoka S, Komori A, Yatsuhashi H, Migita K, Ohira H, Tanaka A, Takikawa H, Nagasaki M, Tokunaga K, Nakamura M; PBC‐GWAS Consortium in Japan. Integrated GWAS and mRNA Microarray Analysis Identified IFNG and CD40L as the Central Upstream Regulators in Primary Biliary Cholangitis. Hepatol Commun 2020;4:724-38. [PMID: 32363322 DOI: 10.1002/hep4.1497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
86 Young GR, Abdelghany TM, Leitch AC, Dunn MP, Blain PG, Lanyon C, Wright MC. Changes in the gut microbiota of mice orally exposed to methylimidazolium ionic liquids. PLoS One 2020;15:e0229745. [PMID: 32163446 DOI: 10.1371/journal.pone.0229745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
87 Zhao DT, Liu YM, Han Y, Zhang HP, Zhao Y, Yan HP. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report. Medicine (Baltimore) 2020;99:e18856. [PMID: 32011506 DOI: 10.1097/MD.0000000000018856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Zhang S, Yu M, Guo F, Yang X, Chen Y, Ma C, Li Q, Wei Z, Li X, Wang H, Hu H, Zhang Y, Kong D, Miao QR, Hu W, Hajjar DP, Zhu Y, Han J, Duan Y. Rosiglitazone alleviates intrahepatic cholestasis induced by α-naphthylisothiocyanate in mice: The role of circulating 15-deoxy-Δ12,14 -PGJ2 and Nogo. Br J Pharmacol 2020;177:1041-60. [PMID: 31658492 DOI: 10.1111/bph.14886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
89 Sayiner M, Stepanova M, De Avila L, Golabi P, Racila A, Younossi ZM. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Dig Dis Sci 2020;65:416-22. [PMID: 31451982 DOI: 10.1007/s10620-019-05786-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
90 Hao YL, Bian ZL, Ju LL, Liu Y, Qin G. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis. Dig Dis Sci 2020;65:470-9. [PMID: 31377883 DOI: 10.1007/s10620-019-05758-5] [Reference Citation Analysis]
91 Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. J Clin Transl Hepatol 2020;8:49-60. [PMID: 32274345 DOI: 10.14218/JCTH.2019.00049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
92 Cheok YY, Lee CYQ, Cheong HC, Looi CY, Wong WF. Chronic Inflammatory Diseases at Secondary Sites Ensuing Urogenital or Pulmonary Chlamydia Infections. Microorganisms 2020;8:E127. [PMID: 31963395 DOI: 10.3390/microorganisms8010127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
93 Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther 2020;51:90-109. [PMID: 31762074 DOI: 10.1111/apt.15579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
94 Moosvi Z, Lui FH, Nguyen D. Assessment of Liver Function. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_35] [Reference Citation Analysis]
95 Chascsa DMH, Lindor KD. Emerging therapies for PBC. J Gastroenterol 2020;55:261-72. [PMID: 31970467 DOI: 10.1007/s00535-020-01664-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
96 Evert M. Intrahepatische Gallenwegserkrankungen. Pathologie 2020. [DOI: 10.1007/978-3-642-04557-8_9] [Reference Citation Analysis]
97 Patterson JW, Kwock J, Flowers R, Guffey D, Pruitt L, Stowman AM, David BAM. Systemic Disease and the Skin. Atlas of Dermatology, Dermatopathology and Venereology 2020. [DOI: 10.1007/978-3-319-45134-3_48-1] [Reference Citation Analysis]
98 Amar MJA, Freeman LA, Nishida T, Sampson ML, Pryor M, Vaisman BL, Neufeld EB, Karathanasis SK, Remaley AT. LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis. Pharmacol Res Perspect 2020;8:e00554. [PMID: 31893124 DOI: 10.1002/prp2.554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
99 Lin H, Zhou C, Hou Y, Li Q, Qiao G, Wang Y, Huang Z, Niu J. Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid. Front Pharmacol 2019;10:1515. [PMID: 31920680 DOI: 10.3389/fphar.2019.01515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
100 Liu Chen Kiow J, Vincent C, Sidani S, Bouin M. High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis. Neurogastroenterol Motil 2019;31:e13691. [PMID: 31373141 DOI: 10.1111/nmo.13691] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
101 Baldo DC, Dellavance A, Ferraz MLG, Andrade LEC. Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Auto Immun Highlights 2019;10:10. [PMID: 32257066 DOI: 10.1186/s13317-019-0120-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
102 Fujino H, Tanaka M, Imamura M, Morio K, Ono A, Nakahara T, Murakami E, Kawaoka T, Takahashi S, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterol 2019;19:169. [PMID: 31651244 DOI: 10.1186/s12876-019-1092-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
103 Younossi ZM, Stepanova M, Golabi P, Epstein RS, Strauss ME, Nader F, Racila A. Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database. J Clin Gastroenterol 2019;53:693-8. [PMID: 30148766 DOI: 10.1097/MCG.0000000000001120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
104 Vespasiani-Gentilucci U, Rosina F, Pace-Palitti V, Sacco R, Pellicelli A, Chessa L, De Vincentis A, Barlattani M, Barlattani A, Feletti V, Mussetto A, Zolfino T, Russello M, Cozzolongo R, Garrucciu G, Niro G, Bacca D, Bertino G, Claar E, Ascione A, D'Adamo G, Adinolfi LE, Scifo G, Izzi A; CLEO-AIGO PBC study group. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. Scand J Gastroenterol 2019;54:1274-82. [PMID: 31564176 DOI: 10.1080/00365521.2019.1669702] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
105 Joshita S, Umemura T, Yamashita Y, Sugiura A, Yamazaki T, Fujimori N, Matsumoto A, Tanaka E. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatol Res 2019;49:1236-43. [PMID: 31077509 DOI: 10.1111/hepr.13361] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
106 Glaser F, John C, Engel B, Höh B, Weidemann S, Dieckhoff J, Stein S, Becker N, Casar C, Schuran FA, Wieschendorf B, Preti M, Jessen F, Franke A, Carambia A, Lohse AW, Ittrich H, Herkel J, Heeren J, Schramm C, Schwinge D. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. J Hepatol 2019;71:783-92. [PMID: 31207266 DOI: 10.1016/j.jhep.2019.05.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
107 Abe K, Fujita M, Hayashi M, Okai K, Takahashi A, Ohira H. Gut and oral microbiota in autoimmune liver disease. Fukushima J Med Sci 2020;65:71-5. [PMID: 31564673 DOI: 10.5387/fms.2019-21] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
108 Agrawal R, Majeed M, Attar BM, Omar YA, Mbachi C, Wang Y, Flores E, Shaqib S, Wang Y, Udechukwu V, Demetria M, Gandhi S. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials. Ann Gastroenterol 2019;32:489-97. [PMID: 31474796 DOI: 10.20524/aog.2019.0403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
109 Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019;71:357-65. [PMID: 30980847 DOI: 10.1016/j.jhep.2019.04.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 25.5] [Reference Citation Analysis]
110 Alomari M, Covut F, Al Momani L, Chadalavada P, Hitawala A, Young MF, Romero-Marrero C. Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population. JGH Open 2020;4:132-9. [PMID: 32280755 DOI: 10.1002/jgh3.12223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Jiang Z, Liu X, Yuan Z, He H, Wang J, Zhang X, Gong Z, Hou L, Shen L, Guo F, Zhang J, Wang J, Xu D, Liu Z, Li H, Chen X, Long C, Li J, Chen S. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. ACS Med Chem Lett 2019;10:1068-73. [PMID: 31312410 DOI: 10.1021/acsmedchemlett.9b00189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
112 Li YK, Li YM, Li Y, Wei YR, Zhang J, Li B, You ZR, Chen Y, Huang BY, Miao Q, Wang QX, Peng YS, Gershwin ME, Tang RQ, Bian ZL, Ma X. CTHRC1 expression in primary biliary cholangitis. J Dig Dis 2019;20:371-6. [PMID: 31102333 DOI: 10.1111/1751-2980.12791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
113 Calise SJ, Zheng B, Hasegawa T, Satoh M, Isailovic N, Ceribelli A, Andrade LEC, Boylan K, Cavazzana I, Fritzler MJ, de la Torre IG, Hiepe F, Kohl K, Selmi C, Shoenfeld Y, Tincani A, Chan EKL; IUIS Autoantibody Standardization Committee. Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. Clin Chem Lab Med 2018;56:1789-98. [PMID: 29478040 DOI: 10.1515/cclm-2017-1152] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
114 Arsenijevic A, Milovanovic J, Stojanovic B, Djordjevic D, Stanojevic I, Jankovic N, Vojvodic D, Arsenijevic N, Lukic ML, Milovanovic M. Gal-3 Deficiency Suppresses Novosphyngobium aromaticivorans Inflammasome Activation and IL-17 Driven Autoimmune Cholangitis in Mice. Front Immunol 2019;10:1309. [PMID: 31231399 DOI: 10.3389/fimmu.2019.01309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
115 Ni P, Men R, Shen M, Wang T, Huang C, Fan X, Yang L. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis. Can J Gastroenterol Hepatol 2019;2019:7396870. [PMID: 31275901 DOI: 10.1155/2019/7396870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
116 Onuorah NK, Wayde M, Beck G. Unusual presentation of pica in iron-deficiency anaemia associated with primary biliary cholangitis. BMJ Case Rep 2019;12:e227316. [PMID: 31147407 DOI: 10.1136/bcr-2018-227316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Porcelli B, Terzuoli L, Bacarelli MR, Cinci F, Bizzaro N. Anticorpi anti-mitocondri con specificità M2, positivi su cellule HEp-2 e negativi su triplo tessuto: indicazioni per una corretta strategia diagnostica. Riv Ital Med Lab 2019;15. [DOI: 10.23736/s1825-859x.19.00006-9] [Reference Citation Analysis]
118 Marzioni M, Bassanelli C, Ripellino C, Urbinati D, Alvaro D. Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database. Dig Liver Dis 2019;51:724-9. [PMID: 30584000 DOI: 10.1016/j.dld.2018.11.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
119 Guillot A, Tacke F. Liver Macrophages: Old Dogmas and New Insights. Hepatol Commun 2019;3:730-43. [PMID: 31168508 DOI: 10.1002/hep4.1356] [Cited by in Crossref: 156] [Cited by in F6Publishing: 167] [Article Influence: 39.0] [Reference Citation Analysis]
120 González-huezo M, Delgado-ayala L, Osorio-núñez A, Meléndez-mercado C. Autoimmune associations in a Mexican cohort with primary biliary cholangitis. Revista de Gastroenterología de México (English Edition) 2019;84:130-135. [DOI: 10.1016/j.rgmxen.2018.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
121 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Changes in serum levels of leucine-rich α2-glycoprotein predict prognosis in primary biliary cholangitis. Hepatol Res 2019;49:385-93. [PMID: 30471232 DOI: 10.1111/hepr.13291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
122 Liu Q, Li Y, Ma X, Tang R. Epigenetics of autoimmune liver diseases: current progress and future directions. Journal of Bio-X Research 2019;2:46-55. [DOI: 10.1097/jbr.0000000000000030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M. POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. Sci Rep 2019;9:102. [PMID: 30643196 DOI: 10.1038/s41598-018-36490-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
124 Abe K, Takahashi A, Ohira H. Liver Cirrhosis with Autoimmune Liver Diseases: AIH and PBC. The Evolving Landscape of Liver Cirrhosis Management 2019. [DOI: 10.1007/978-981-13-7979-6_2] [Reference Citation Analysis]
125 Phillips PK, Said A. Diseases of the Liver: Primary Biliary Cholangitis. Gastrointestinal and Liver Disorders in Women’s Health 2019. [DOI: 10.1007/978-3-030-25626-5_7] [Reference Citation Analysis]
126 Perricone C, Versini M, Ben-ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, Cantarini L, Bogdanos DP, Antonelli A, Amital H, Valesini G, Shoenfeld Y. Smoke and Autoimmunity. Mosaic of Autoimmunity 2019. [DOI: 10.1016/b978-0-12-814307-0.00037-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Sayiner M, Golabi P, Stepanova M, Younossi I, Nader F, Racila A, Younossi ZM. Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. Hepatology 2019;69:237-44. [PMID: 30015376 DOI: 10.1002/hep.30174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
128 Takahashi A, Ohira H. Liver Involvement in Rheumatic Diseases. Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases 2019. [DOI: 10.1007/978-981-13-6524-9_1] [Reference Citation Analysis]
129 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019;69:394-419. [PMID: 30070375 DOI: 10.1002/hep.30145] [Cited by in Crossref: 152] [Cited by in F6Publishing: 174] [Article Influence: 38.0] [Reference Citation Analysis]
130 Gkoutzourelas A, Liaskos C, Mytilinaiou MG, Simopoulou T, Katsiari C, Tsirogianni A, Daoussis D, Scheper T, Meyer W, Bogdanos DP, Sakkas LI. Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis. Front Immunol 2018;9:2835. [PMID: 30581434 DOI: 10.3389/fimmu.2018.02835] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
131 Hitomi Y, Nakatani K, Kojima K, Nishida N, Kawai Y, Kawashima M, Aiba Y, Nagasaki M, Nakamura M, Tokunaga K. NFKB1 and MANBA Confer Disease Susceptibility to Primary Biliary Cholangitis via Independent Putative Primary Functional Variants. Cell Mol Gastroenterol Hepatol 2019;7:515-32. [PMID: 30528300 DOI: 10.1016/j.jcmgh.2018.11.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
132 Huang S, Zheng J, Yang Q, Chen G, Xu J, Shen Y, Zhang Y, Ouyang G. High-Efficiency, Matrix Interference-Free, General Applicable Probes for Bile Acids Extraction and Detection. Adv Sci (Weinh) 2018;5:1800774. [PMID: 30581699 DOI: 10.1002/advs.201800774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
133 Yoshitake S, Murakami T, Suzuma K, Yoshitake T, Uji A, Morooka S, Dodo Y, Fujimoto M, Shan Y, Fort PE, Ito S, Tsujikawa A, Yoshimura N. Anti-fumarase antibody promotes the dropout of photoreceptor inner and outer segments in diabetic macular oedema. Diabetologia 2019;62:504-16. [PMID: 30488085 DOI: 10.1007/s00125-018-4773-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
134 Luo J, Xu S, Lv Y, Huang X, Zhang H, Zhu X, Wang X. Clinical features and potential relevant factors of renal involvement in primary Sjögren's syndrome. Int J Rheum Dis 2019;22:182-90. [PMID: 30411528 DOI: 10.1111/1756-185X.13429] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
135 Moritoki Y, Tsuneyama K, Nakamura Y, Kikuchi K, Shiota A, Ohsugi Y, Lian ZX, Zhang W, Yang GX, Ueki S, Takeda M, Omokawa A, Saga T, Saga A, Watanabe D, Miura M, Ueno Y, Leung PSC, Tanaka A, Gershwin ME, Hirokawa M. Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice. Front Immunol 2018;9:2534. [PMID: 30450101 DOI: 10.3389/fimmu.2018.02534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
136 Probert PM, Leitch AC, Dunn MP, Meyer SK, Palmer JM, Abdelghany TM, Lakey AF, Cooke MP, Talbot H, Wills C, McFarlane W, Blake LI, Rosenmai AK, Oskarsson A, Figueiredo R, Wilson C, Kass GE, Jones DE, Blain PG, Wright MC. Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis. J Hepatol 2018;69:1123-35. [PMID: 30006067 DOI: 10.1016/j.jhep.2018.06.027] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
137 Peng JK, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of patients with end-stage liver disease: A systematic review and meta-analysis. Palliat Med 2019;33:24-36. [PMID: 30345878 DOI: 10.1177/0269216318807051] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 17.8] [Reference Citation Analysis]
138 Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, Matsuzaki Y, Ohira H, Yoshiji H, Takikawa H; Japan PBC Study Group (JPBCSG). Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol 2018;53:1151-8. [PMID: 29663077 DOI: 10.1007/s00535-018-1465-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
139 Yu H, Li Y, Xu Z, Wang D, Shi S, Deng H, Zeng B, Zheng Z, Sun L, Deng X, Zhong X. Identification of potential biomarkers in cholestasis and the therapeutic effect of melatonin by metabolomics, multivariate data and pathway analyses. Int J Mol Med 2018;42:2515-26. [PMID: 30226547 DOI: 10.3892/ijmm.2018.3859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
140 Goldstein J, Levy C. Novel and emerging therapies for cholestatic liver diseases. Liver Int 2018;38:1520-35. [PMID: 29758112 DOI: 10.1111/liv.13880] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
141 Yagi M, Tanaka A, Abe M, Namisaki T, Yoshiji H, Takahashi A, Ohira H, Komori A, Yamagiwa S, Kikuchi K, Yasunaka T, Takaki A, Ueno Y, Honda A, Matsuzaki Y, Takikawa H. Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. Sci Rep 2018;8:12542. [PMID: 30135523 DOI: 10.1038/s41598-018-31063-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
142 Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018;94:7-15. [PMID: 30115527 DOI: 10.1016/j.jaut.2018.08.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
143 Chascsa DM, Lindor KD. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease? Clin Liver Dis 2018;22:589-601. [PMID: 30259855 DOI: 10.1016/j.cld.2018.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
144 Park S, Song HR, Lee SW, Lee TH. Wouldn't Human Understanding be Necessary to Treat Patients with Pancreaticobiliary Disease More Effectively? Korean J Pancreas Biliary Tract 2018;23:89-100. [DOI: 10.15279/kpba.2018.23.3.89] [Reference Citation Analysis]
145 Abe K, Takahashi A, Fujita M, Imaizumi H, Hayashi M, Okai K, Ohira H. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 2018;13:e0198757. [PMID: 29969462 DOI: 10.1371/journal.pone.0198757] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
146 Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review. J Clin Transl Hepatol 2018;6:119-26. [PMID: 29951355 DOI: 10.14218/JCTH.2017.00064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
147 Nguyen HH, Khathlan A, Fritzler MJ, Swain MG. A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. BMC Gastroenterol 2018;18:97. [PMID: 29940867 DOI: 10.1186/s12876-018-0826-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
148 Setsu T, Yamagiwa S, Tominaga K, Kimura N, Honda H, Kamimura H, Tsuchiya A, Takamura M, Terai S. Persistent reduction of mucosal-associated invariant T cells in primary biliary cholangitis. J Gastroenterol Hepatol 2018;33:1286-94. [PMID: 29266628 DOI: 10.1111/jgh.14076] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
149 Yu D, Cai SY, Mennone A, Vig P, Boyer JL. Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int 2018;38:1128-38. [PMID: 29356312 DOI: 10.1111/liv.13698] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
150 Zollner G, Prattes J, Nemeth A. Primär biliäre Cholangitis in Graz: Präsentation, Verlauf und Outcome. J Gastroenterol Hepatol Erkr 2018;16:56-62. [DOI: 10.1007/s41971-018-0028-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
151 Chew M, Bowlus CL. Primary biliary cholangitis: Diagnosis and treatment. Liver Research 2018;2:81-6. [DOI: 10.1016/j.livres.2018.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
152 Cholankeril G, Gonzalez HC, Satapathy SK, Gonzalez SA, Hu M, Khan MA, Yoo ER, Li AA, Kim D, Nair S, Wong RJ, Kwo PY, Harrison SA, Younossi ZM, Lindor KD, Ahmed A. Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol 2018;16:965-973.e2. [PMID: 29427734 DOI: 10.1016/j.cgh.2017.12.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
153 Joshita S, Umemura T, Usami Y, Yamashita Y, Norman GL, Sugiura A, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Yoshizawa K, Ota M, Tanaka E. Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. Sci Rep 2018;8:8159. [PMID: 29802350 DOI: 10.1038/s41598-018-26531-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
154 Nishida N, Aiba Y, Hitomi Y, Kawashima M, Kojima K, Kawai Y, Ueno K, Nakamura H, Yamashiki N, Tanaka T, Tamura S, Mori A, Yagi S, Soejima Y, Yoshizumi T, Takatsuki M, Tanaka A, Harada K, Shimoda S, Komori A, Eguchi S, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M. NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population. Sci Rep 2018;8:8071. [PMID: 29795304 DOI: 10.1038/s41598-018-26369-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
155 Im C, Sapkota Y, Moon W, Kawashima M, Nakamura M, Tokunaga K, Yasui Y. Genome-wide haplotype association analysis of primary biliary cholangitis risk in Japanese. Sci Rep 2018;8:7806. [PMID: 29773854 DOI: 10.1038/s41598-018-26112-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
156 Li C, Dhyani M, Bhan AK, Grajo JR, Pratt DS, Gee MS, Samir AE. Diagnostic Performance of Shear Wave Elastography in Patients With Autoimmune Liver Disease. J Ultrasound Med. 2018;. [PMID: 29761535 DOI: 10.1002/jum.14668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
157 Glassner K, Quigley EM, Franco L, Victor DW 3rd. Autoimmune liver disease and the enteric microbiome. AIMS Microbiol 2018;4:334-46. [PMID: 31294219 DOI: 10.3934/microbiol.2018.2.334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
158 Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology 2018;67:1920-30. [PMID: 29220537 DOI: 10.1002/hep.29717] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 8.2] [Reference Citation Analysis]
159 Ye W, Chen S, Huang X, Qin W, Zhang T, Zhu X, Zhu X, Lin C, Wang X. Clinical features and risk factors of neurological involvement in Sjögren's syndrome. BMC Neurosci 2018;19:26. [PMID: 29703151 DOI: 10.1186/s12868-018-0427-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
160 Rodríguez-Carrio J, Mozo L, López P, Nikiphorou E, Suárez A. Anti-High-Density Lipoprotein Antibodies and Antioxidant Dysfunction in Immune-Driven Diseases. Front Med (Lausanne) 2018;5:114. [PMID: 29740582 DOI: 10.3389/fmed.2018.00114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
161 Honda M, Kubes P. Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system. Nat Rev Gastroenterol Hepatol 2018;15:206-21. [PMID: 29382950 DOI: 10.1038/nrgastro.2017.183] [Cited by in Crossref: 102] [Cited by in F6Publishing: 102] [Article Influence: 20.4] [Reference Citation Analysis]
162 Erice O, Munoz-Garrido P, Vaquero J, Perugorria MJ, Fernandez-Barrena MG, Saez E, Santos-Laso A, Arbelaiz A, Jimenez-Agüero R, Fernandez-Irigoyen J, Santamaria E, Torrano V, Carracedo A, Ananthanarayanan M, Marzioni M, Prieto J, Beuers U, Oude Elferink RP, LaRusso NF, Bujanda L, Marin JJG, Banales JM. MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. Hepatology 2018;67:1420-40. [PMID: 28922472 DOI: 10.1002/hep.29533] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
163 de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, Richardson P, Moreea S, McCune CA, Ryder SD, Chapman RW, Floreani A, Jones DE, de Min C, Adams DH, Invernizzi P. NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatol Commun 2018;2:492-503. [PMID: 29761166 DOI: 10.1002/hep4.1170] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
164 Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q, Yang F, Miao Q, Xiao X, Zhang H, Lian M, Jiang X, Zhang J, Cao Q, Fan Z, Wu M, Qiu D, Fang JY, Ansari A, Gershwin ME, Ma X. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018;67:534-41. [PMID: 28213609 DOI: 10.1136/gutjnl-2016-313332] [Cited by in Crossref: 217] [Cited by in F6Publishing: 198] [Article Influence: 43.4] [Reference Citation Analysis]
165 Zhang W, De D, Mohammed KA, Munigala S, Chen G, Lai JP, Bacon BR. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun 2018;2:245-53. [PMID: 29507900 DOI: 10.1002/hep4.1148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
166 Alfano AM, Romito A, Marchese C, Battistini M, Crotti G, Ferrini A, Mancinetti C, Manetta T, Mengozzi G, Merlach P, Migliardi M, Tambuzzo MT. Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease? Immunol Res 2017;65:299-306. [PMID: 27475095 DOI: 10.1007/s12026-016-8838-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
167 Wakabayashi SI, Kimura T, Tanaka N, Joshita S, Kawata K, Umemura T, Hiroshima Y, Mori H, Kobayashi H, Wada S, Tanaka E. Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. Clin J Gastroenterol 2018;11:302-8. [PMID: 29428971 DOI: 10.1007/s12328-018-0831-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
168 Barbouche MR, Chen Q, Carbone M, Ben-Mustapha I, Shums Z, Trifa M, Malinverno F, Bernuzzi F, Zhang H, Agrebi N, Norman GL, Chang C, Gershwin ME, Invernizzi P. Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. Cell Mol Immunol 2018;15:610-7. [PMID: 29400703 DOI: 10.1038/cmi.2017.140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
169 Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR; Global PBC Study Group. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. Am J Gastroenterol 2018;113:254-64. [PMID: 29231188 DOI: 10.1038/ajg.2017.440] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 10.2] [Reference Citation Analysis]
170 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Nozawa Y, Ohira H. Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. Med Mol Morphol 2018;51:176-85. [PMID: 29380060 DOI: 10.1007/s00795-018-0184-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
171 Zhang W, Zhang R, Zhang J, Sun Y, Leung PS, Yang GX, Shuai Z, Ridgway WM, Gershwin ME. Proteomic analysis reveals distinctive protein profiles involved in CD8+ T cell-mediated murine autoimmune cholangitis. Cell Mol Immunol 2018;15:756-67. [PMID: 29375127 DOI: 10.1038/cmi.2017.149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
172 Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, Norman GL, Veres G, Par G, Par A, Szalay F, Lakatos PL, Antal-Szalmas P, Papp M. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep 2018;8:399. [PMID: 29321484 DOI: 10.1038/s41598-017-18622-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
173 Araki Y, Mimura T. Epigenetic Basis of Autoimmune Disorders in Humans. Epigenetics in Human Disease 2018. [DOI: 10.1016/b978-0-12-812215-0.00012-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
174 Nagaratnam N, Nagaratnam K, Cheuk G. Chronic Liver Disease. Geriatric Diseases 2018. [DOI: 10.1007/978-3-319-33434-9_22] [Reference Citation Analysis]
175 Kakar S. Primary Biliary Cholangitis. Practical Hepatic Pathology: a Diagnostic Approach 2018. [DOI: 10.1016/b978-0-323-42873-6.00026-3] [Reference Citation Analysis]
176 Ju C, Phillips E, Holt M, Gao Y, Lammert C. The Adaptive Immune System and Liver Toxicity. Comprehensive Toxicology 2018. [DOI: 10.1016/b978-0-12-801238-3.95663-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
177 Marzorati S, Lleo A, Invernizzi P. The Epigenetics of Primary Biliary Cholangitis. The Epigenetics of Autoimmunity 2018. [DOI: 10.1016/b978-0-12-809912-4.00013-1] [Reference Citation Analysis]
178 Zen Y, Hübscher SG, Nakanuma Y. Bile Duct Diseases. Macsween's Pathology of the Liver 2018. [DOI: 10.1016/b978-0-7020-6697-9.00009-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
179 Ide R, Oshita A, Nishisaka T, Nakahara H, Aimitsu S, Itamoto T. Primary biliary cholangitis metachronously complicated with combined hepatocellular carcinoma-cholangiocellular carcinoma and hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1378-1384 [PMID: 29359023 DOI: 10.4254/wjh.v9.i36.1378] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
180 Deng CW, Wang L, Fei YY, Hu CJ, Yang YJ, Peng LY, Zeng XF, Zhang FC, Li YZ. Exploring pathogenesis of primary biliary cholangitis by proteomics: A pilot study. World J Gastroenterol 2017; 23(48): 8489-8499 [PMID: 29358857 DOI: 10.3748/wjg.v23.i48.8489] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
181 Yang YQ, Yang W, Yao Y, Ma HD, Wang YH, Li L, Wu Q, Gershwin ME, Lian ZX. Dysregulation of peritoneal cavity B1a cells and murine primary biliary cholangitis. Oncotarget 2016;7:26992-7006. [PMID: 27105495 DOI: 10.18632/oncotarget.8853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
182 Evlice M, Aksoz Z. Thyrotoxicosis associated with severe hypoalbuminemia and hyperbilirubinemia. Egypt J Intern Med 2017;29:196-198. [DOI: 10.4103/ejim.ejim_7_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
183 Lewis J. Pathological patterns of biliary disease. Clin Liver Dis (Hoboken) 2017;10:107-10. [PMID: 30992767 DOI: 10.1002/cld.667] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
184 Chen J, Hou X, Jia H, Cui G, Wu Z, Wang L, Lu C, Wu W, Wei Y, Uede T, Li L, Lian Z, Diao H. Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis. Oncotarget 2017;8:108406-17. [PMID: 29312539 DOI: 10.18632/oncotarget.22658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
185 Joshita S, Umemura T, Tanaka E, Ota M. Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. Clin J Gastroenterol 2018;11:11-8. [PMID: 29159718 DOI: 10.1007/s12328-017-0799-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
186 Huang W, Rainbow DB, Wu Y, Adams D, Shivakumar P, Kottyan L, Karns R, Aronow B, Bezerra J, Gershwin ME, Peterson LB, Wicker LS, Ridgway WM. A Novel Pkhd1 Mutation Interacts with the Nonobese Diabetic Genetic Background To Cause Autoimmune Cholangitis. J Immunol 2018;200:147-62. [PMID: 29158418 DOI: 10.4049/jimmunol.1701087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
187 Ma WT, Liu QZ, Yang JB, Yang YQ, Zhao ZB, Ma HD, Gershwin ME, Lian ZX. A Mouse Model of Autoimmune Cholangitis via Syngeneic Bile Duct Protein Immunization. Sci Rep 2017;7:15246. [PMID: 29127360 DOI: 10.1038/s41598-017-15661-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
188 Tanaka A, Leung PSC, Young HA, Gershwin ME. Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans. Arch Med Sci 2018;14:930-40. [PMID: 30002712 DOI: 10.5114/aoms.2017.70995] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Levy C, Carrion AF, Mayo MJ. Primary Biliary Cholangitis. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch21] [Reference Citation Analysis]
190 Resorlu H, Kılıc S, Isık S, Gokmen F. Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea. Acta Clin Belg 2017;72:365-8. [PMID: 28229620 DOI: 10.1080/17843286.2017.1290567] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
191 Noguerón García A, Hernán Calvo F, Viguera Garrido L, Abizanda Soler P. Hemorragia digestiva baja secundaria a pólipo por émbolo de colesterol como primera manifestación de cirrosis biliar primaria en un mayor. Revista Española de Geriatría y Gerontología 2017;52:288-290. [DOI: 10.1016/j.regg.2017.03.004] [Reference Citation Analysis]
192 Di Sabatino A, Biagi F, Lenzi M, Frulloni L, Lenti MV, Giuffrida P, Corazza GR. Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. Dig Liver Dis 2017;49:947-56. [PMID: 28733178 DOI: 10.1016/j.dld.2017.06.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
193 Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Adv Ther 2017;34:2120-38. [PMID: 28808886 DOI: 10.1007/s12325-017-0601-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
194 Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8:e116. [PMID: 28858291 DOI: 10.1038/ctg.2017.43] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
195 Konishi H, Fukuzawa K, Mori S, Satomi-Kobayashi S, Kiuchi K, Suzuki A, Yano Y, Yoshida A, Hirata KI. Anti-mitochondrial M2 Antibodies Enhance the Risk of Supraventricular Arrhythmias in Patients with Elevated Hepatobiliary Enzyme Levels. Intern Med 2017;56:1771-9. [PMID: 28717071 DOI: 10.2169/internalmedicine.56.8183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
196 Lin L, Piao M, Jiang X, Lv H, Zhao N, Yang F, Sun C. Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort. BMJ Open. 2017;7:e015304. [PMID: 28706093 DOI: 10.1136/bmjopen-2016-015304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
197 Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Auto Immun Highlights 2017;8:9. [PMID: 28647912 DOI: 10.1007/s13317-017-0097-2] [Cited by in Crossref: 87] [Cited by in F6Publishing: 98] [Article Influence: 14.5] [Reference Citation Analysis]
198 Hitomi Y, Kojima K, Kawashima M, Kawai Y, Nishida N, Aiba Y, Yasunami M, Nagasaki M, Nakamura M, Tokunaga K. Identification of the functional variant driving ORMDL3 and GSDMB expression in human chromosome 17q12-21 in primary biliary cholangitis. Sci Rep 2017;7:2904. [PMID: 28588209 DOI: 10.1038/s41598-017-03067-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
199 Li Z, Lin B, Lin G, Wu Y, Jie Y, Li X, Ko B, Chong Y, Luo J. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS One 2017;12:e0178580. [PMID: 28570655 DOI: 10.1371/journal.pone.0178580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
200 Nakagawa R, Muroyama R, Saeki C, Goto K, Kaise Y, Koike K, Nakano M, Matsubara Y, Takano K, Ito S, Saruta M, Kato N, Zeniya M. miR-425 regulates inflammatory cytokine production in CD4(+) T cells via N-Ras upregulation in primary biliary cholangitis. J Hepatol 2017;66:1223-30. [PMID: 28192189 DOI: 10.1016/j.jhep.2017.02.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
201 Tanakaa A, Leung PS, Young HA, Gershwin ME. Toward solving the etiological mystery of primary biliary cholangitis. Hepatol Commun 2017;1:275-87. [PMID: 29057387 DOI: 10.1002/hep4.1044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
202 Kogiso T, Egawa H, Teramukai S, Taniai M, Hashimoto E, Tokushige K, Sakisaka S, Sakabayashi S, Yamamoto M, Umeshita K, Uemoto S. Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study. Hepatol Commun 2017;1:394-405. [PMID: 29404468 DOI: 10.1002/hep4.1037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
203 Thomson J, Hargrove L, Kennedy L, Demieville J, Francis H. Cellular crosstalk during cholestatic liver injury. Liver Res 2017;1:26-33. [PMID: 29552372 DOI: 10.1016/j.livres.2017.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
204 Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res 2017;1:3-9. [PMID: 29104811 DOI: 10.1016/j.livres.2017.05.001] [Cited by in Crossref: 124] [Cited by in F6Publishing: 135] [Article Influence: 20.7] [Reference Citation Analysis]
205 Toh BH. Diagnostic autoantibodies for autoimmune liver diseases. Clin Transl Immunology 2017;6:e139. [PMID: 28690845 DOI: 10.1038/cti.2017.14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
206 Tang L, Zhong R, He X, Wang W, Liu J, Zhu Y, Li Y, Hou J. Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis. J Gastroenterol Hepatol 2017;32:659-66. [PMID: 27529417 DOI: 10.1111/jgh.13534] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
207 Yang F, Yang Y, Wang Q, Wang Z, Miao Q, Xiao X, Wei Y, Bian Z, Sheng L, Chen X, Qiu D, Fang J, Tang R, Gershwin ME, Ma X. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther 2017;45:733-43. [PMID: 28083929 DOI: 10.1111/apt.13927] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
208 Li P, Lu G, Cui Y, Wu Z, Chen S, Li J, Wen X, Zhang H, Mu S, Zhang F. Association of IL12A Expression Quantitative Trait Loci (eQTL) With Primary Biliary Cirrhosis in a Chinese Han Population. Medicine (Baltimore). 2016;95:e3665. [PMID: 27175695 DOI: 10.1097/md.0000000000003665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
209 Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther 2017;45:485-500. [PMID: 27957759 DOI: 10.1111/apt.13894] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 12.0] [Reference Citation Analysis]
210 Joshita S, Umemura T, Tanaka E, Ota M. Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. J Immunol Res. 2017;2017:3073504. [PMID: 28255561 DOI: 10.1155/2017/3073504] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
211 Kempinska-Podhorodecka A, Milkiewicz M, Wasik U, Ligocka J, Zawadzki M, Krawczyk M, Milkiewicz P. Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-miRNA155-SOCS1 Pathway. Int J Mol Sci 2017;18:E289. [PMID: 28146070 DOI: 10.3390/ijms18020289] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
212 Ma HD, Ma WT, Liu QZ, Zhao ZB, Liu MZ, Tsuneyama K, Gao JM, Ridgway WM, Ansari AA, Gershwin ME, Fei YY, Lian ZX. Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8+ T cell activation. J Autoimmun 2017;78:19-28. [PMID: 28129932 DOI: 10.1016/j.jaut.2016.12.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
213 Wang L, Bowlus CL, Wang F, Gershwin ME. Primary Biliary Cholangitis: Its Science and Practice. Biliary Disease 2017. [DOI: 10.1007/978-3-319-50168-0_8] [Reference Citation Analysis]
214 Dahlqvist G, Gaouar F, Carrat F, Meurisse S, Chazouillères O, Poupon R, Johanet C, Corpechot C; French network of Immunology Laboratories. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 2017;65:152-63. [PMID: 27688145 DOI: 10.1002/hep.28859] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
215 Martin EF. Miscellaneous Disorders: Pregnancy-Associated Liver Disorders, Vascular Disorders, Granulomatous Diseases, and Amyloidosis. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_26] [Reference Citation Analysis]
216 Tanaka A. Bile Acids and Cholestatic Liver Disease 1: Primary Biliary Cholangitis (PBC). Bile Acids in Gastroenterology 2017. [DOI: 10.1007/978-4-431-56062-3_7] [Reference Citation Analysis]
217 Nagaratnam N, Nagaratnam K, Cheuk G. Chronic Liver Disease. Geriatric Diseases 2017. [DOI: 10.1007/978-3-319-32700-6_22-1] [Reference Citation Analysis]
218 Primary Biliary Cholangitis. Diagnostic Pathology: Hepatobiliary and Pancreas 2017. [DOI: 10.1016/b978-0-323-44307-4.50044-0] [Reference Citation Analysis]
219 Boberg KM. The Clinical Burden of Biliary Disease: A Global Perspective. Biliary Disease 2017. [DOI: 10.1007/978-3-319-50168-0_1] [Reference Citation Analysis]
220 Kwon WH, Park HM, Park JJ, Lee SH, Lee YK. A Case of Primary Biliary Cirrhosis Mimicking Acute Hepatitis B in the Clinic, Republic of Korea. Korean J Fam Med 2017;38:43. [DOI: 10.4082/kjfm.2017.38.1.43] [Reference Citation Analysis]
221 Ali AH, Carey EJ, Lindor KD. Autoimmune Liver Diseases: Primary Biliary Cholangitis. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_16] [Reference Citation Analysis]
222 Abdalian R, Heathcote J, Ramos-casals M. Primary Biliary Cholangitisa. The Digestive Involvement in Systemic Autoimmune Diseases 2017. [DOI: 10.1016/b978-0-444-63707-9.00005-2] [Reference Citation Analysis]
223 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Primary biliary cholangitis: new treatments for an old disease. Frontline Gastroenterol 2017;8:29-36. [PMID: 28839882 DOI: 10.1136/flgastro-2016-100741] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
224 Brown DL. Immunopathology of the Hepatobiliary System. Immunopathology in Toxicology and Drug Development 2017. [DOI: 10.1007/978-3-319-47385-7_7] [Reference Citation Analysis]
225 Yang L, Zhang H, Jiang YF, Jin QL, Zhang P, Li X, Gao PJ, Niu JQ. Association of Estrogen Receptor Gene Polymorphisms and Primary Biliary Cirrhosis in a Chinese Population: A Case-Control Study. Chin Med J (Engl). 2015;128:3008-3014. [PMID: 26608979 DOI: 10.4103/0366-6999.168964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
226 Mattner J. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC). Int J Mol Sci. 2016;17. [PMID: 27834858 DOI: 10.3390/ijms17111864] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
227 Liberal R, Grant CR. Cirrhosis and autoimmune liver disease: Current understanding. World J Hepatol 2016; 8(28): 1157-1168 [PMID: 27729952 DOI: 10.4254/wjh.v8.i28.1157] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
228 Bae HR, Leung PS, Tsuneyama K, Valencia JC, Hodge DL, Kim S, Back T, Karwan M, Merchant AS, Baba N, Feng D, Park O, Gao B, Yang GX, Gershwin ME, Young HA. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 2016;64:1189-201. [PMID: 27178326 DOI: 10.1002/hep.28641] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 9.9] [Reference Citation Analysis]
229 Vergani D, Mieli-Vergani G. Mouse model of primary biliary cholangitis with a striking female predominance: A new powerful research tool. Hepatology 2016;64:1024-7. [PMID: 27388433 DOI: 10.1002/hep.28718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
230 Koksal D, Koksal AS, Gurakar A. Pulmonary Manifestations among Patients with Primary Biliary Cirrhosis. J Clin Transl Hepatol 2016;4:258-62. [PMID: 27777894 DOI: 10.14218/JCTH.2016.00024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
231 Lleo A, Bian Z, Zhang H, Miao Q, Yang F, Peng Y, Chen X, Tang R, Wang Q, Qiu D, Fang J, Sobacchi C, Villa A, Di Tommaso L, Roncalli M, Gershwin ME, Ma X, Invernizzi P. Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS One 2016;11:e0159612. [PMID: 27631617 DOI: 10.1371/journal.pone.0159612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
232 Hua F, Wang L, Rong X, Hu Y, Zhang JM, He W, Zhang FC. Elevation of Vδ1 T cells in peripheral blood and livers of patients with primary biliary cholangitis. Clin Exp Immunol 2016;186:347-55. [PMID: 27543908 DOI: 10.1111/cei.12852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
233 Concepcion AR, Salas JT, Sáez E, Sarvide S, Ferrer A, Portu A, Uriarte I, Hervás-Stubbs S, Oude Elferink RP, Prieto J. CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis. Oncotarget. 2015;6:28588-28606. [PMID: 26396175 DOI: 10.18632/oncotarget.5665] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
234 Teegen EM, Krebs I, Langelotz C, Pratschke J, Rau B. Gender Mainstreaming and Transplant Surgery. Visc Med 2016;32:286-9. [PMID: 27722166 DOI: 10.1159/000446357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
235 Umemura T, Joshita S, Yamazaki T, Komatsu M, Katsuyama Y, Yoshizawa K, Tanaka E, Ota M. Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan. Sci Rep 2016;6:29770. [PMID: 27406031 DOI: 10.1038/srep29770] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
236 Mitra S, Minz RW. Autoantibodies in Autoimmune Liver Diseases-Methods of Detection and Interpretation: An Update for the Reporting Pathologist. Int J Surg Pathol 2016;24:576-85. [PMID: 27388199 DOI: 10.1177/1066896916657643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
237 Wickramasinghe RD, Luke WA, Sebastiampillai BS, Gunathilake MP, Premaratna R. Thyrotoxic crisis presenting with jaundice. BMC Res Notes 2016;9:320. [PMID: 27338936 DOI: 10.1186/s13104-016-2126-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
238 Liang DY, Hou YQ, Luo LJ, Ao L. Altered expression of miR-92a correlates with Th17 cell frequency in patients with primary biliary cirrhosis. Int J Mol Med 2016;38:131-8. [PMID: 27246196 DOI: 10.3892/ijmm.2016.2610] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
239 Lleo A, Jepsen P, Morenghi E, Carbone M, Moroni L, Battezzati PM, Podda M, Mackay IR, Gershwin ME, Invernizzi P. Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Sci Rep. 2016;6:25906. [PMID: 27192935 DOI: 10.1038/srep25906] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 12.4] [Reference Citation Analysis]
240 Wong KC. How to apply clinical cases and medical literature in the framework of a modified "failure mode and effects analysis" as a clinical reasoning tool--an illustration using the human biliary system. J Med Case Rep 2016;10:85. [PMID: 27048215 DOI: 10.1186/s13256-016-0850-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
241 Li P, Lu G, Wang L, Cui Y, Wu Z, Chen S, Li J, Wen X, Zhang H, Mu S. A rare nonsynonymous variant in the lipid metabolic gene HELZ2 related to primary biliary cirrhosis in Chinese Han. Allergy Asthma Clin Immunol. 2016;12:14. [PMID: 27047549 DOI: 10.1186/s13223-016-0120-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
242 Suzuki Y, Ishida K, Takahashi H, Koeda N, Kakisaka K, Miyamoto Y, Suzuki A, Takikawa Y. Primary biliary cirrhosis associated with Graves' disease in a male patient. Clin J Gastroenterol 2016;9:99-103. [PMID: 26935935 DOI: 10.1007/s12328-016-0635-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
243 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol 2016;6:73-6. [PMID: 27194902 DOI: 10.1016/j.jceh.2016.03.005] [Reference Citation Analysis]
244 Shi T, Zhang T, Zhang L, Yang Y, Zhang H, Zhang F. The Distribution and the Fibrotic Role of Elevated Inflammatory Th17 Cells in Patients With Primary Biliary Cirrhosis. Medicine (Baltimore). 2015;94:e1888. [PMID: 26554784 DOI: 10.1097/md.0000000000001888] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
245 Javaid A, Poongkunran M, Allard FD, Kyaw W, Maung HH, Lau D. Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report. Gastroenterol Rep (Oxf). 2016; Epub ahead of print. [PMID: 26893441 DOI: 10.1093/gastro/gov064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
246 Tang R, Wei Y, Li Z, Chen H, Miao Q, Bian Z, Zhang H, Wang Q, Wang Z, Lian M, Yang F, Jiang X, Yang Y, Li E, Seldin MF, Gershwin ME, Liao W, Shi Y, Ma X. A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density. Sci Rep 2016;6:19877. [PMID: 26842849 DOI: 10.1038/srep19877] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
247 Ecker J, Lammert F, Gluud LL, Stokes CS. Bile acid derivatives for people with primary biliary cholangitis. Cochrane Database of Systematic Reviews 2016. [DOI: 10.1002/14651858.cd012062] [Reference Citation Analysis]
248 Bekki N, Bae SK, Yoshizawa S, Shiota A, Gushima T, Motoshita J, Shimoda S, Aiba Y, Komori A, Nakamura M, Takahashi K. A case of primary biliary cirrhosis in a patient with rheumatoid arthritis. Clin Case Rep 2016;4:90-4. [PMID: 26783445 DOI: 10.1002/ccr3.449] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
249 Lefkowitch JH. Biliary Disease. Scheuer's Liver Biopsy Interpretation 2016. [DOI: 10.1016/b978-0-7020-5548-5.00005-0] [Reference Citation Analysis]
250 Ungprasert P, Wijarnpreecha K, Thongprayoon C. Risk of cerebrovascular accident in patients with primary biliary cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016;28:90-4. [PMID: 26473301 DOI: 10.1097/MEG.0000000000000493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
251 Takahashi A, Abe K, Watanabe H, Ohira H. Rheumatic Diseases and the Liver. The Liver in Systemic Diseases 2016. [DOI: 10.1007/978-4-431-55790-6_13] [Reference Citation Analysis]
252 Sun Y, Zhang W, Li B, Zou Z, Selmi C, Gershwin ME. The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review. Clin Rev Allergy Immunol 2015;48:301-15. [PMID: 25682089 DOI: 10.1007/s12016-015-8471-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
253 Harada K. IgG4-Related Diseases and the Liver. The Liver in Systemic Diseases 2016. [DOI: 10.1007/978-4-431-55790-6_15] [Reference Citation Analysis]
254 Sun Y, Haapanen K, Li B, Zhang W, Van de Water J, Gershwin ME. Women and primary biliary cirrhosis. Clin Rev Allergy Immunol 2015;48:285-300. [PMID: 25241227 DOI: 10.1007/s12016-014-8449-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
255 Tahtaci M, Yurekli OT, Bolat AD, Balci S, Akin FE, Buyukasik NS, Ersoy O. Increased mean platelet volume is related to histologic severity of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2015;27:1382-5. [PMID: 26308712 DOI: 10.1097/MEG.0000000000000463] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
256 Shimoda S, Hisamoto S, Harada K, Iwasaka S, Chong Y, Nakamura M, Bekki Y, Yoshizumi T, Shirabe K, Ikegami T, Maehara Y, He XS, Gershwin ME, Akashi K. Natural killer cells regulate T cell immune responses in primary biliary cirrhosis. Hepatology 2015;62:1817-27. [PMID: 26264889 DOI: 10.1002/hep.28122] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
257 Cominelli F, Arseneau KO, Hamilton MJ, Blumberg RS. The Mucosal Immune System and Gastrointestinal Inflammation. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch17] [Reference Citation Analysis]
258 Noor F. A shift in paradigm towards human biology-based systems for cholestatic-liver diseases. J Physiol 2015;593:5043-55. [PMID: 26417843 DOI: 10.1113/JP271124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
259 Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol 2015;27:1175-9. [PMID: 26148248 DOI: 10.1097/MEG.0000000000000424] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
260 Yang JB, Wang YH, Yang W, Lu FT, Ma HD, Zhao ZB, Jia YJ, Tang W, Tsuneyama K, Ridgway WM, Gershwin ME, Lian ZX. Successful treatment of murine autoimmune cholangitis by parabiosis: Implications for hematopoietic therapy. J Autoimmun 2016;66:108-17. [PMID: 26432598 DOI: 10.1016/j.jaut.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
261 Dimopoulou D, Dimitroulas T, Akriviadis E, Garyfallos A. Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis. Rheumatol Int 2015;35:1913-6. [PMID: 26411882 DOI: 10.1007/s00296-015-3366-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
262 Tomiyama T, Yang GX, Zhao M, Zhang W, Tanaka H, Wang J, Leung PS, Okazaki K, He XS, Lu Q. The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cell Mol Immunol. 2017;14:276-284. [PMID: 26388238 DOI: 10.1038/cmi.2015.86] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
263 Sasaki M, Yoshimura-Miyakoshi M, Sato Y, Nakanuma Y. A possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary cirrhosis. J Gastroenterol 2015;50:984-95. [PMID: 25552342 DOI: 10.1007/s00535-014-1033-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
264 Bao XY, Xu BB, Fang K, Li Y, Hu YH, Yu GP. Changing trends of hospitalisation of liver cirrhosis in Beijing, China. BMJ Open Gastroenterol 2015;2:e000051. [PMID: 26629359 DOI: 10.1136/bmjgast-2015-000051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
265 Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempińska-Podhorodecka A, Elias E, Barbier O, Milkiewicz P. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Sci Rep 2015;5:13462. [PMID: 26293907 DOI: 10.1038/srep13462] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
266 Sasaki M, Hsu M, Yeh MM, Nakanuma Y. In recurrent primary biliary cirrhosis after liver transplantation, biliary epithelial cells show increased expression of mitochondrial proteins. Virchows Arch. 2015;467:417-425. [PMID: 26259963 DOI: 10.1007/s00428-015-1819-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
267 Kouroumalis E, Notas G. Primary biliary cirrhosis: From bench to bedside. World J Gastrointest Pharmacol Ther 2015; 6(3): 32-58 [PMID: 26261733 DOI: 10.4292/wjgpt.v6.i3.32] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
268 Lombardi A, Inabnet WB 3rd, Owen R, Farenholtz KE, Tomer Y. Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis. J Clin Endocrinol Metab 2015;100:E1-10. [PMID: 25295624 DOI: 10.1210/jc.2014-2745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
269 Reshetnyak VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World J Gastroenterol 2015; 21(25): 7683-7708 [PMID: 26167070 DOI: 10.3748/wjg.v21.i25.7683] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
270 Lleo A, Zhang W, Zhao M, Tan Y, Bernuzzi F, Zhu B, Liu Q, Tan Q, Malinverno F, Valenti L, Jiang T, Tan L, Liao W, Coppel R, Invernizzi P, Lu Q, Adams DH, Gershwin ME; PBC Epigenetic Study Group. DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. Clin Epigenetics. 2015;7:61. [PMID: 26150899 DOI: 10.1186/s13148-015-0098-9] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 9.1] [Reference Citation Analysis]
271 Begum R, Mahtab MA, Al Mamun A, Kumar Saha B, Shahadat Hossain SM, Chandra Das D, Fazle Akbar SM, Kamal M, Rahman S. A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature. Euroasian J Hepatogastroenterol 2015;5:122-6. [PMID: 29201708 DOI: 10.5005/jp-journals-10018-1150] [Reference Citation Analysis]
272 Sekiguchi T, Umemura T, Fujimori N, Shibata S, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E, Ota M. Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One 2015;10:e0131658. [PMID: 26110613 DOI: 10.1371/journal.pone.0131658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
273 Marin JJ, Bujanda L, Banales JM. MicroRNAs and cholestatic liver diseases. Curr Opin Gastroenterol. 2014;30:303-309 [PMID: 24553410 DOI: 10.1097/MOG.0000000000000051]3 Zhang L, Ma D, Li X, Deng C, Shi Q, You X, Leng X, Li M, Tang F, Zhang F, Li Y. Gene expression profiles of peripheral blood mononuclear cells in primary biliary cirrhosis. Clin Exp Med 2014; 14: 409-416. [PMID: 23958878 DOI: 10.1007/s10238-013-0253-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
274 Verdier J, Luedde T, Sellge G. Biliary Mucosal Barrier and Microbiome. Viszeralmedizin. 2015;31:156-161. [PMID: 26468308 DOI: 10.1159/000431071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
275 Tang YM, Wang JP, Bao WM, Yang JH, Ma LK, Yang J, Chen H, Xu Y, Yang LH, Li W. Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis. Int J Mol Med. 2015;36:377-385. [PMID: 26046127 DOI: 10.3892/ijmm.2015.2233] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
276 Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, Komatsu M, Matsumoto A, Ota M, Tanaka E. Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. Am J Gastroenterol 2015;110:857-64. [PMID: 25916223 DOI: 10.1038/ajg.2015.118] [Cited by in Crossref: 101] [Cited by in F6Publishing: 90] [Article Influence: 12.6] [Reference Citation Analysis]
277 Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients. J Clin Gastroenterol 2015;49:438-47. [PMID: 25014239 DOI: 10.1097/MCG.0000000000000176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
278 Hitomi Y, Kawashima M, Aiba Y, Nishida N, Matsuhashi M, Okazaki H, Nakamura M, Tokunaga K. Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1. Hum Genet 2015;134:737-47. [PMID: 25899471 DOI: 10.1007/s00439-015-1556-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
279 Wang L, Guo GY, Wang JB, Zhou XM, Yang Q, Han ZY, Li Q, Zhang JW, Cai Y, Ren XL, Zhou X, Chen RR, Shi YQ, Han Y, Fan DM. A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis. Sci Rep 2015;5:9772. [PMID: 25894308 DOI: 10.1038/srep09772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
280 Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: does sex matter? J Hepatol 2015;62:946-55. [PMID: 25433162 DOI: 10.1016/j.jhep.2014.11.023] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 7.3] [Reference Citation Analysis]
281 Zhang XX, Wang LF, Jin L, Li YY, Hao SL, Shi YC, Zeng QL, Li ZW, Zhang Z, Lau GK, Wang FS. Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: Incidence and risk factors. World J Gastroenterol 2015; 21(12): 3554-3563 [PMID: 25834320 DOI: 10.3748/wjg.v21.i12.3554] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
282 Maruyama H, Kondo T, Sekimoto T, Takahashi M, Fujiwara K, Imazeki F, Yokosuka O. Retrograde detection of the intrahepatic portal vein in primary biliary cirrhosis: is sinusoidal blockage the underlying pathophysiology? Eur J Gastroenterol Hepatol 2015;27:321-7. [PMID: 25563140 DOI: 10.1097/MEG.0000000000000268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
283 Wang YH, Yang W, Yang JB, Jia YJ, Tang W, Gershwin ME, Ridgway WM, Lian ZX. Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis. J Autoimmun 2015;59:26-37. [PMID: 25701076 DOI: 10.1016/j.jaut.2015.01.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
284 Wang L, Sun Y, Zhang Z, Jia Y, Zou Z, Ding J, Li Y, Xu X, Jin L, Yang T, Li Z, Sun Y, Zhang JY, Lv S, Chen L, Li B, Gershwin ME, Wang FS. CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 2015;61:627-38. [PMID: 25042122 DOI: 10.1002/hep.27306] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 11.3] [Reference Citation Analysis]
285 Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB, Rothschild KJ, Bowlus CL, Adamopoulos IE, Leung PS, Janssen HJ, Cheung AC, Coltescu C, Gershwin ME. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int 2015;35:642-51. [PMID: 25243383 DOI: 10.1111/liv.12690] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
286 Baik SK, Kim MY, Jeong WK. Diagnostic imaging modalities. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch03] [Reference Citation Analysis]
287 Yang Y, Lin H. Diagnostic laboratory tests. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch02] [Reference Citation Analysis]
288 Smyk DS, Rigopoulou EI, Invernizzi P, Bogdanos DP. Infection and Autoimmune Liver Diseases. Infection and Autoimmunity 2015. [DOI: 10.1016/b978-0-444-63269-2.00075-1] [Reference Citation Analysis]
289 Bogdanos D, Leung PS, Gershwin ME. Liver and the Biliary Tract. Mucosal Immunology 2015. [DOI: 10.1016/b978-0-12-415847-4.00087-2] [Reference Citation Analysis]
290 Kim JY, Kim TH, Yoo K, Han YJ, Choi JE, Kim JY, Cho M. Clinical Features and Response to UDCA Treatment of Primary Biliary Cirrhosis. Ewha Med J 2015;38:106. [DOI: 10.12771/emj.2015.38.3.106] [Reference Citation Analysis]
291 Bell LN, Wulff J, Comerford M, Vuppalanchi R, Chalasani N. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int 2015;35:263-74. [PMID: 25181933 DOI: 10.1111/liv.12680] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
292 Mousa HS, Lleo A, Invernizzi P, Bowlus CL, Gershwin ME. Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother. 2015;16:633-643. [PMID: 25543678 DOI: 10.1517/14656566.2015.998650] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
293 Li L, Ruau DJ, Patel CJ, Weber SC, Chen R, Tatonetti NP, Dudley JT, Butte AJ. Disease risk factors identified through shared genetic architecture and electronic medical records. Sci Transl Med 2014;6:234ra57. [PMID: 24786325 DOI: 10.1126/scitranslmed.3007191] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
294 Koutsoumpas AL, Smyk DS, Bogdanos DP. E. coli Induced Experimental Model of Primary Biliary Cirrhosis: At Last. Int J Hepatol 2014;2014:848373. [PMID: 25580301 DOI: 10.1155/2014/848373] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
295 Marchioni Beery RM, Vaziri H, Forouhar F. Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. J Clin Transl Hepatol 2014;2:266-84. [PMID: 26357630 DOI: 10.14218/JCTH.2014.00024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
296 Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Parés A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE; Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-49.e5; quiz e15. [PMID: 25160979 DOI: 10.1053/j.gastro.2014.08.029] [Cited by in Crossref: 279] [Cited by in F6Publishing: 291] [Article Influence: 31.0] [Reference Citation Analysis]
297 Liu F, Pan ZG, Ye J, Xu D, Guo H, Li GP, Xu KS, Hou XH, Song YH. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients. J Dig Dis 2014;15:660-8. [PMID: 25236944 DOI: 10.1111/1751-2980.12196] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
298 Malinowski M, Jara M, Lüttgert K, Orr J, Lock JF, Schott E, Stockmann M. Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test. Dig Dis Sci 2014;59:2983-91. [PMID: 24993690 DOI: 10.1007/s10620-014-3250-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
299 Saverino D, Pesce G, Antola P, Porcelli B, Brusca I, Villalta D, Tampoia M, Tozzoli R, Tonutti E, Alessio MG, Bagnasco M, Bizzaro N. High levels of soluble CTLA-4 are present in anti-mitochondrial antibody positive, but not in antibody negative patients with primary biliary cirrhosis. PLoS One 2014;9:e112509. [PMID: 25383768 DOI: 10.1371/journal.pone.0112509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
300 Shaik FB, Prasad DV, Narala VR. Role of farnesoid X receptor in inflammation and resolution. Inflamm Res. 2015;64:9-20. [PMID: 25376338 DOI: 10.1007/s00011-014-0780-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
301 Paul S, Sepehr GJ, Weinstein B, Roper J. Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Dig Dis Sci 2014;59:2831-5. [PMID: 25108519 DOI: 10.1007/s10620-014-3216-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
302 Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable Rare Dis Res 2012;1:66-80. [PMID: 25343075 DOI: 10.5582/irdr.2012.v1.2.66] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
303 Chen RR, Li YJ, Zhou XM, Wang L, Xing J, Han S, Cui LN, Zheng LH, Wu KC, Shi YQ, Han ZY, Han Y, Fan DM. The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid response. Dis Markers 2014;2014:350690. [PMID: 25392597 DOI: 10.1155/2014/350690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
304 Katsushima F, Takahashi A, Sakamoto N, Kanno Y, Abe K, Ohira H. Expression of micro-RNAs in peripheral blood mononuclear cells from primary biliary cirrhosis patients. Hepatol Res 2014;44:E189-97. [PMID: 23834361 DOI: 10.1111/hepr.12198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
305 Lleo A, Zhang W, McDonald WH, Seeley EH, Leung PS, Coppel RL, Ansari AA, Adams DH, Afford S, Invernizzi P, Gershwin ME. Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 2014;60:1314-23. [PMID: 24841946 DOI: 10.1002/hep.27230] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
306 Martínez AK, Maroni L, Marzioni M, Ahmed ST, Milad M, Ray D, Alpini G, Glaser SS. Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies. Curr Pathobiol Rep 2014;2:143-53. [PMID: 25396098 DOI: 10.1007/s40139-014-0050-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
307 Lammert C, Juran BD, Schlicht E, Xie X, Atkinson EJ, de Andrade M, Lazaridis KN. Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clin Gastroenterol Hepatol 2014;12:1562-8. [PMID: 24440215 DOI: 10.1016/j.cgh.2013.12.036] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
308 Deep HS, Jain J, Grover AS. PRIMARY BILIARY CIRRHOSIS ASSOCIATION WITH RHEUMATOID ARTHRITIS: A RARE CASE PRESENTATION. jemds 2014;3:10117-10119. [DOI: 10.14260/jemds/2014/3312] [Reference Citation Analysis]
309 Henstridge DC, Whitham M, Febbraio MA. Chaperoning to the metabolic party: The emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes. Mol Metab 2014;3:781-93. [PMID: 25379403 DOI: 10.1016/j.molmet.2014.08.003] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 7.4] [Reference Citation Analysis]
310 Hoffmann K, Hinz U, Hillebrand N, Ganten T, Gotthardt D, Longerich T, Schirmacher P, Schemmer P. The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases. Langenbecks Arch Surg. 2014;399:1001-1009. [PMID: 25106131 DOI: 10.1007/s00423-014-1237-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
311 Liaskou E, Hirschfield GM, Gershwin ME. Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol. 2014;36:553-568. [PMID: 25082647 DOI: 10.1007/s00281-014-0439-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
312 Zollner G, Trauner M. Cholestase – Update 2014. Wien Klin Wochenschr Educ 2014;8:73-90. [DOI: 10.1007/s11812-014-0061-2] [Reference Citation Analysis]
313 Lleo A, Maroni L, Glaser S, Alpini G, Marzioni M. Role of cholangiocytes in primary biliary cirrhosis. Semin Liver Dis 2014;34:273-84. [PMID: 25057951 DOI: 10.1055/s-0034-1383727] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
314 Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis 2014;34:265-72. [PMID: 25057950 DOI: 10.1055/s-0034-1383726] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
315 Hu SL, Zhao FR, Hu Q, Chen WX. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One 2014;9:e101916. [PMID: 25010534 DOI: 10.1371/journal.pone.0101916] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
316 Yamagiwa S, Kamimura H, Takamura M, Genda T, Ichida T, Nomoto M, Aoyagi Y. Presence of antibodies against self human leukocyte antigen class II molecules in autoimmune hepatitis. Int J Med Sci 2014;11:850-6. [PMID: 25013363 DOI: 10.7150/ijms.8633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
317 Barlogis V. Esplenomegalia en el niño. EMC - Pediatría 2014;49:1-7. [DOI: 10.1016/s1245-1789(14)67273-5] [Reference Citation Analysis]
318 Cuperus FJ, Halilbasic E, Trauner M. Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol 2014;30:279-86. [PMID: 24625898 DOI: 10.1097/MOG.0000000000000056] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
319 Devuni D, Chokshi RV. Developing a fellowship curriculum in women's gastrointestinal health. Gastroenterology 2014;146:1151-5. [PMID: 24662330 DOI: 10.1053/j.gastro.2014.03.021] [Reference Citation Analysis]
320 Harnois DM, Yataco ML, Nakhleh RE. Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation. Clin Liver Dis (Hoboken) 2014;3:90-2. [PMID: 30992894 DOI: 10.1002/cld.341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
321 Bloch DB, Li P, Bloch EG, Berenson DF, Galdos RL, Arora P, Malhotra R, Wu C, Yang W. LMKB/MARF1 localizes to mRNA processing bodies, interacts with Ge-1, and regulates IFI44L gene expression. PLoS One 2014;9:e94784. [PMID: 24755989 DOI: 10.1371/journal.pone.0094784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
322 Kobayashi M, Kakuda Y, Harada K, Sato Y, Sasaki M, Ikeda H, Terada M, Mukai M, Kaneko S, Nakanuma Y. Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol 2014; 20(13): 3597-3608 [PMID: 24707143 DOI: 10.3748/wjg.v20.i13.3597] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
323 Li YJ, Tang YW, Shi YQ, Han S, Wang JB, Zhou XM, Chen Y, Wu ZD, Han ZY, Han Y, Wu KC, Fan DM. Polymorphisms in the vitamin D receptor gene and risk of primary biliary cirrhosis: a meta-analysis. J Gastroenterol Hepatol 2014;29:706-15. [PMID: 24224838 DOI: 10.1111/jgh.12443] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
324 Ludvigsson JF, Bergquist A, Montgomery SM, Bahmanyar S. Risk of diabetes and cardiovascular disease in patients with primary sclerosing cholangitis. J Hepatol 2014;60:802-8. [PMID: 24291242 DOI: 10.1016/j.jhep.2013.11.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
325 Invernizzi P, Bernuzzi F, Lleo A, Pozzoli V, Bignotto M, Zermiani P, Crosignani A, Battezzati PM, Zuin M, Podda M, Raggi C. Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Dig Liver Dis 2014;46:363-8. [PMID: 24378524 DOI: 10.1016/j.dld.2013.11.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
326 Yamagiwa S, Kamimura H, Takamura M, Aoyagi Y. Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol 2014; 20(10): 2606-2612 [PMID: 24627596 DOI: 10.3748/wjg.v20.i10.2606] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
327 Durazzo M, Belci P, Collo A, Prandi V, Pistone E, Martorana M, Gambino R, Bo S. Gender specific medicine in liver diseases: A point of view. World J Gastroenterol 2014; 20(9): 2127-2135 [PMID: 24605011 DOI: 10.3748/wjg.v20.i9.2127] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
328 Huang W, Kachapati K, Adams D, Wu Y, Leung PS, Yang GX, Zhang W, Ansari AA, Flavell RA, Gershwin ME. Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells. J Autoimmun. 2014;50:123-134. [PMID: 24556277 DOI: 10.1016/j.jaut.2014.01.034] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
329 McNally RJ, James PW, Ducker S, Norman PD, James OF. No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England. Am J Epidemiol 2014;179:492-8. [PMID: 24401563 DOI: 10.1093/aje/kwt308] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
330 Mo C, Lu Y, Deng Y, Wang J, Xie L, Li T, He Y, Qin X, Li S. Lack of association between vitamin D receptor gene ApaI, BsmI, and TaqI polymorphisms and primary biliary cirrhosis risk: a meta-analysis. Tumour Biol. 2014;35:4913-4920. [PMID: 24526415 DOI: 10.1007/s13277-014-1645-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
331 Joshita S, Umemura T, Nakamura M, Katsuyama Y, Shibata S, Kimura T, Morita S, Komatsu M, Matsumoto A, Yoshizawa K. STAT4 gene polymorphisms are associated with susceptibility and ANA status in primary biliary cirrhosis. Dis Markers. 2014;2014:727393. [PMID: 24648611 DOI: 10.1155/2014/727393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
332 Zhao DT, Liao HY, Zhang X, Liu YM, Zhao Y, Zhang HP, Sun LM, Ma YX, Yan HP. Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis. Liver Int 2014;34:220-6. [PMID: 23809616 DOI: 10.1111/liv.12236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
333 Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2014;59:580-91. [PMID: 23913513 DOI: 10.1002/hep.26664] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 8.9] [Reference Citation Analysis]
334 Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Sakkas L, Pouria S, Shoenfeld Y. Tracing environmental markers of autoimmunity: introducing the infectome. Immunol Res 2013;56:220-40. [PMID: 23592050 DOI: 10.1007/s12026-013-8399-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
335 Mohammed JP, Mattner J. Autoimmune disease triggered by infection with alphaproteobacteria. Expert Rev Clin Immunol 2009;5:369-79. [PMID: 20161124 DOI: 10.1586/ECI.09.23] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
336 Shi TY, Zhang FC. Role of autoimmunity in primary biliary cirrhosis. World J Gastroenterol. 2012;18:7141-7148. [PMID: 23326118 DOI: 10.3748/wjgv.18.i48.7141] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
337 Jo Y, Kim MY, Kim H, Lee YK, Kang HJ, Kim JH. A Comparative Evaluation of the Performances of Anti-MIT3, Anti-gp210, and Anti-sp100 Antibodies for the Diagnosis of Primary Biliary Cirrhosis. Lab Med Online 2014;4:91. [DOI: 10.3343/lmo.2014.4.2.91] [Reference Citation Analysis]
338 Han JY, Lee KH, Seo MR, Choi HJ. Successful Treatment of Primary Biliary Cirrhosis with Adalimumab in a Patient with Overlap Syndrome. J Rheum Dis 2014;21:322. [DOI: 10.4078/jrd.2014.21.6.322] [Reference Citation Analysis]
339 Invernizzi P, Leung PSC, Ma X, Gershwin ME. Primary Biliary Cirrhosis. Liver Immunology 2014. [DOI: 10.1007/978-3-319-02096-9_18] [Reference Citation Analysis]
340 Kim JE, Choo HG, Yoon IN. A Case of Recurrent Uveitis in Autoimmune Liver Disease. J Korean Ophthalmol Soc 2014;55:1257. [DOI: 10.3341/jkos.2014.55.8.1257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
341 Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44 Suppl S1:71-90. [PMID: 24397841 DOI: 10.1111/hepr.12270] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 7.2] [Reference Citation Analysis]
342 Kakuda Y, Harada K, Nakanuma Y. New Histological Staging and Grading System for Primary Biliary Cirrhosis. Autoimmune Liver Diseases 2014. [DOI: 10.1007/978-4-431-54789-1_16] [Reference Citation Analysis]
343 Moritoki Y, Ueno Y. Animal Models for Primary Biliary Cirrhosis. Autoimmune Liver Diseases 2014. [DOI: 10.1007/978-4-431-54789-1_14] [Reference Citation Analysis]
344 Al Mamari S, Chapman RW, Boberg KM. Overlap Syndromes. Liver Immunology 2014. [DOI: 10.1007/978-3-319-02096-9_21] [Reference Citation Analysis]
345 Park HS. Cholangitis. Radiology Illustrated 2014. [DOI: 10.1007/978-3-642-35825-8_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
346 Tang V, Friedman J. Biliary Disease. Pathobiology of Human Disease 2014. [DOI: 10.1016/b978-0-12-386456-7.04211-8] [Reference Citation Analysis]
347 Aso-ishimoto Y, Yamagiwa S, Ichida T, Miyakawa R, Tomiyama C, Sato Y, Watanabe H, Aoyagi Y. Increased activated natural killer T cells in the liver of patients with advancedstage primary biliary cirrhosis. Biomed Res 2014;35:161-169. [DOI: 10.2220/biomedres.35.161] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
348 Abhyankar A, Tapper E, Bonder A. Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient. Pharmaceuticals (Basel). 2013;7:18-28. [PMID: 24380894 DOI: 10.3390/ph7010018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
349 Mališová L, Kováčová Z, Koc M, Kračmerová J, Stich V, Rossmeislová L. Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One 2013;8:e82086. [PMID: 24312631 DOI: 10.1371/journal.pone.0082086] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
350 Papastergiou V, Tsochatzis EA, Rodriguez-Peralvarez M, Thalassinos E, Pieri G, Manousou P, Germani G, Rigamonti C, Arvaniti V, Karatapanis S, Burroughs AK. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther 2013;38:1354-64. [PMID: 24117847 DOI: 10.1111/apt.12522] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
351 Bogdanos DP, Gao B, Gershwin ME. Liver immunology. Compr Physiol. 2013;3:567-598. [PMID: 23720323 DOI: 10.1002/cphy.c120011] [Cited by in Crossref: 85] [Cited by in F6Publishing: 104] [Article Influence: 8.5] [Reference Citation Analysis]
352 Smyk DS, Mytilinaiou MG, Grammatikopoulos T, Knisely AS, Mieli-Vergani G, Bogdanos DP, Vergani D. Primary biliary cirrhosis-specific antimitochondrial antibodies in neonatal haemochromatosis. Clin Dev Immunol 2013;2013:642643. [PMID: 24171034 DOI: 10.1155/2013/642643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
353 Buryova H, Chalupsky K, Zbodakova O, Kanchev I, Jirouskova M, Gregor M, Sedlacek R. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity. BMC Gastroenterol 2013;13:155. [PMID: 24172289 DOI: 10.1186/1471-230X-13-155] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
354 Landi A, Weismuller TJ, Lankisch TO, Santer DM, Tyrrell DL, Manns MP, Houghton M. Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. J Interferon Cytokine Res. 2014;34:204-214. [PMID: 24168449 DOI: 10.1089/jir.2013.0075] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
355 Sfakianaki O, Tzardi M, Voumvouraki A, Afgoustaki A, Koulentaki M, Kouroumalis E. Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis. World J Hepatol 2013; 5(10): 568-576 [PMID: 24179616 DOI: 10.4254/wjh.v5.i10.568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
356 Mattner J. Natural killer T (NKT) cells in autoimmune hepatitis. Curr Opin Immunol. 2013;25:697-703. [PMID: 24148235 DOI: 10.1016/j.coi.2013.09.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
357 Abe M, Hiasa Y, Onji M. T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol. 2013;2013:607073. [PMID: 24223606 DOI: 10.1155/2013/607073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
358 Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl 2013;19:1065-77. [PMID: 23873751 DOI: 10.1002/lt.23704] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
359 Inamine T, Higa S, Noguchi F, Kondo S, Omagari K, Yatsuhashi H, Tsukamoto K, Nakamura M. Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 2013;48:1160-70. [PMID: 23354620 DOI: 10.1007/s00535-012-0730-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
360 Liu B, Zhang X, Zhang FC, Zong JB, Zhang W, Zhao Y. Aberrant TGF-β1 signaling contributes to the development of primary biliary cirrhosis in murine model. World J Gastroenterol 2013; 19(35): 5828-5836 [PMID: 24124327 DOI: 10.3748/wjg.v19.i35.5828] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
361 Tang J, Lu J, Yan HP. Diagnostic and predictive significance of autoantibody profiles in autoimmune liver disease. Shijie Huaren Xiaohua Zazhi 2013; 21(25): 2544-2550 [DOI: 10.11569/wcjd.v21.i25.2544] [Reference Citation Analysis]
362 Cash WJ, O'Neill S, O'Donnell ME, McCance DR, Young IS, McEneny J, McDougall NI, Callender ME. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013;33:1166-74. [PMID: 23672463 DOI: 10.1111/liv.12191] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
363 Papp M, Sipeki N, Vitalis Z, Tornai T, Altorjay I, Tornai I, Udvardy M, Fechner K, Jacobsen S, Teegen B, Sumegi A, Veres G, Lakatos PL, Kappelmayer J, Antal-Szalmas P. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis. J Hepatol 2013;59:457-66. [PMID: 23639483 DOI: 10.1016/j.jhep.2013.04.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
364 Kawata K, Yang GX, Ando Y, Tanaka H, Zhang W, Kobayashi Y, Tsuneyama K, Leung PS, Lian ZX, Ridgway WM, Ansari AA, He XS, Gershwin ME. Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFβRII mice. Hepatology 2013;58:1094-104. [PMID: 23532950 DOI: 10.1002/hep.26418] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
365 Lleo A, Invernizzi P. Apotopes and innate immune system: novel players in the primary biliary cirrhosis scenario. Dig Liver Dis 2013;45:630-6. [PMID: 23415798 DOI: 10.1016/j.dld.2013.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
366 Wang J, Budamagunta MS, Voss JC, Kurth MJ, Lam KS, Lu L, Kenny TP, Bowlus C, Kikuchi K, Coppel RL. Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. J Immunol. 2013;191:2126-2133. [PMID: 23894195 DOI: 10.4049/jimmunol.1301092] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
367 Tsochatzis EA, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK. Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy. Biomed Res Int. 2013;2013:139763. [PMID: 23984317 DOI: 10.1155/2013/139763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
368 Kawata K, Kobayashi Y, Gershwin ME, Bowlus CL. The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Rev Allergy Immunol. 2012; Jun 12. [Epub ahead of print]. [PMID: 22689287 DOI: 10.1007/s12016-012-8324-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
369 Mells GF, Pells G, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, Neuberger JM, Day DB, Ducker SJ, Sandford RN, Alexander GJ, Jones DE; UK-PBC Consortium. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 2013;58:273-83. [PMID: 23471852 DOI: 10.1002/hep.26365] [Cited by in Crossref: 121] [Cited by in F6Publishing: 101] [Article Influence: 12.1] [Reference Citation Analysis]
370 Zhang LN, Shi TY, Shi XH, Wang L, Yang YJ, Liu B, Gao LX, Shuai ZW, Kong F, Chen H, Han W, Han SM, Fei YY, Cui QC, Wang Q, Shen M, Xu D, Zheng WJ, Li YZ, Zhang W, Zhang X, Zhang FC. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013;58:264-72. [PMID: 23408380 DOI: 10.1002/hep.26322] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
371 Lammert C, Nguyen DL, Juran BD, Schlicht E, Larson JJ, Atkinson EJ, Lazaridis KN. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Dig Liver Dis 2013;45:589-94. [PMID: 23490343 DOI: 10.1016/j.dld.2013.01.028] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
372 Zhang B, Hu M, Zhang P, Cao H, Wang Y, Wang Z, Su T. BAFF promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis. Braz J Med Biol Res 2013;46:433-9. [PMID: 23681290 DOI: 10.1590/1414-431X20132665] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
373 Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, Ichida T, Nakanuma Y. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology 2013;57:1942-9. [PMID: 23197466 DOI: 10.1002/hep.26176] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
374 Cao SS, Zimmermann EM, Chuang BM, Song B, Nwokoye A, Wilkinson JE, Eaton KA, Kaufman RJ. The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice. Gastroenterology 2013;144:989-1000.e6. [PMID: 23336977 DOI: 10.1053/j.gastro.2013.01.023] [Cited by in Crossref: 153] [Cited by in F6Publishing: 160] [Article Influence: 15.3] [Reference Citation Analysis]
375 Keitel V, Häussinger D. TGR5 in cholangiocytes. Curr Opin Gastroenterol 2013;29:299-304. [PMID: 23429467 DOI: 10.1097/MOG.0b013e32835f3f14] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
376 Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, Saito Y, Takikawa H, Imawari M, Matsuzaki Y. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013;57:1931-41. [PMID: 22911624 DOI: 10.1002/hep.26018] [Cited by in Crossref: 130] [Cited by in F6Publishing: 112] [Article Influence: 13.0] [Reference Citation Analysis]
377 Raszeja-Wyszomirska J, Wunsch E, Kempinska-Podhorodecka A, Smyk DS, Bogdanos DP, Milkiewicz M, Milkiewicz P. TRAF1-C5 affects quality of life in patients with primary biliary cirrhosis. Clin Dev Immunol. 2013;2013:510547. [PMID: 23710202 DOI: 10.1155/2013/510547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
378 Rong GH, Yang GX, Ando Y, Zhang W, He XS, Leung PS, Coppel RL, Ansari AA, Zhong R, Gershwin ME. Human intrahepatic biliary epithelial cells engulf blebs from their apoptotic peers. Clin Exp Immunol. 2013;172:95-103. [PMID: 23480189 DOI: 10.1111/cei.12046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
379 Tajiri K, Tsuneyama K, Miyazono T, Kawai K, Minemura M, Sugiyama T. A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab. Case Rep Gastroenterol 2013;7:195-201. [PMID: 23687488 DOI: 10.1159/000351173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
380 Mells GF, Hirschfield GM. Genetics of Primary Biliary Cirrhosis. In: John Wiley & Sons, Ltd, editor. eLS. Wiley; 2001. [DOI: 10.1002/9780470015902.a0024406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
381 Chen RC, Naiyanetr P, Shu SA, Wang J, Yang GX, Kenny TP, Guggenheim KC, Butler JD, Bowlus C, Tao MH, Kurth MJ, Ansari AA, Kaplan M, Coppel RL, Lleo A, Gershwin ME, Leung PS. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 2013;57:1498-508. [PMID: 23184636 DOI: 10.1002/hep.26157] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
382 Qin B, Huang F, Liang Y, Yang Z, Zhong R. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2013;28:543-50. [PMID: 23173724 DOI: 10.1111/jgh.12040] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
383 Carey EJ, Mayer AP, Files JA. Tired of Being Tired. Journal of Women's Health 2013;22:289-290. [DOI: 10.1089/jwh.2012.4225] [Reference Citation Analysis]
384 Shi TY, Zhang LN, Chen H, Wang L, Shen M, Zhang X, Zhang FC. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol 2013; 19(7): 1111-1118 [PMID: 23467321 DOI: 10.3748/wjg.v19.i7.1111] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
385 Huang YL, Yao DK, Hu ZD, Sun Y, Chen SX, Zhong RQ, Deng AM. Value of baseline platelet count for prediction of complications in primary biliary cirrhosis patients treated with ursodeoxycholic acid. Scand J Clin Lab Invest 2013;73:17-23. [PMID: 23294193 DOI: 10.3109/00365513.2012.731709] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
386 Li S, Ma D, Zhang L, Li X, Deng C, Qin X, Zhang T, Wang L, Shi Q, Wang Q, Wu Q, Zhang X, Zhang F, Li Y. High levels of FCγR3A and PRF1 expression in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Dig Dis Sci 2013;58:458-64. [PMID: 23179144 DOI: 10.1007/s10620-012-2456-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
387 Popov Y. Mouse model of primary biliary cirrhosis with progressive fibrosis: are we there yet? Hepatology 2013;57:429-31. [PMID: 22815060 DOI: 10.1002/hep.25969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
388 Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. Liver Int 2013;33:312-20. [PMID: 23231002 DOI: 10.1111/liv.12049] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
389 Smyk DS, Rigopoulou EI, Bogdanos DP. Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What’s New? Curr Infect Dis Rep. 2013;15:14-24. [PMID: 23188623 DOI: 10.1007/s11908-012-0304-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
390 Kim MS, Kim YS, Kim SG, Byun JM, Yoon LY, Han DH, Moon JJ, Nam J, Kim T, Lee SH, Jung SW, Kim HS, Kim BS, Kim HK. The Clinical Significance of Simplified Scoring Criteria as a Diagnostic Tool for Overlap Syndrome in Korea. Korean J Med 2013;84:211. [DOI: 10.3904/kjm.2013.84.2.211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
391 Bellucci R, Alyea EP. Harnessing Allogeneic Immunity for Anti-myeloma Response. Advances in Biology and Therapy of Multiple Myeloma 2013. [DOI: 10.1007/978-1-4614-5260-7_5] [Reference Citation Analysis]
392 Kaplan M. Primary Biliary Cirrhosis. Encyclopedia of Biological Chemistry 2013. [DOI: 10.1016/b978-0-12-378630-2.00086-4] [Reference Citation Analysis]
393 Bloch DB, Nobre RA, Yang WH. GW/P-bodies and autoimmune disease. Adv Exp Med Biol 2013;768:61-70. [PMID: 23224965 DOI: 10.1007/978-1-4614-5107-5_5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
394 Yeh BM, Downey RT. Benign Diseases of the Biliary Ducts. Abdominal Imaging 2013. [DOI: 10.1007/978-3-642-13327-5_145] [Reference Citation Analysis]
395 Zakko L, Finch J, Rothe MJ, Grant-kels JM. Primary Biliary Cirrhosis: Dermatological Features. Atlas of Dermatological Manifestations of Gastrointestinal Disease 2013. [DOI: 10.1007/978-1-4614-6191-3_66] [Reference Citation Analysis]
396 Manfredi R, Baglio I, De Iorio M, Camera L, Mucelli RP. Cholangitis. Magnetic Resonance Cholangiopancreatography (MRCP) 2013. [DOI: 10.1007/978-88-470-2844-9_4] [Reference Citation Analysis]
397 Zakko L. Primary Biliary Cirrhosis: Gastrointestinal Features. Atlas of Dermatological Manifestations of Gastrointestinal Disease 2013. [DOI: 10.1007/978-1-4614-6191-3_65] [Reference Citation Analysis]
398 Shi TY, Zhang FC. Role of autoimmunity in primary biliary cirrhosis. World J Gastroenterol 2012; 18(48): 7141-7148 [PMID: 23326118 DOI: 10.3748/wjg.v18.i48.7141] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
399 Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2013;12:726-740. [PMID: 23266520 DOI: 10.1016/j.autrev.2012.12.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 6.4] [Reference Citation Analysis]
400 Jung HE, Jang JY, Jeong SW, Kim JN, Jang HY, Cho YJ, Woo SA, Lee SH, Kim SG, Cha SW. Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score. Clin Mol Hepatol. 2012;18:375-382. [PMID: 23323253 DOI: 10.3350/cmh.2012.18.4.375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
401 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551.pub3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 50] [Article Influence: 2.0] [Reference Citation Analysis]
402 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551] [Cited by in Crossref: 24] [Cited by in F6Publishing: 42] [Article Influence: 2.2] [Reference Citation Analysis]
403 Dellavance A, Cançado EL, Abrantes-Lemos CP, Harriz M, Marvulle V, Andrade LE. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2013;7:775-84. [PMID: 23853697 DOI: 10.1007/s12072-012-9413-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
404 Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med. 2012;4:61-71. [PMID: 24367233 DOI: 10.2147/HMER.S25998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
405 Bianchi I, Lleo A, Bernuzzi F, Caliari L, Smyk DS, Invernizzi P. The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. Auto Immun Highlights 2012;3:127-32. [PMID: 26000136 DOI: 10.1007/s13317-012-0043-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
406 Qin B, Liang Y, Yang Z, Zhong R. Effect of the polymorphisms of tumor necrosis factor-α gene on the susceptibility to primary biliary cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol 2012;24:1386-92. [PMID: 23011034 DOI: 10.1097/MEG.0b013e3283581f2e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
407 Oliveira EM, Oliveira PM, Becker V, Dellavance A, Andrade LE, Lanzoni V, Silva AE, Ferraz ML. Overlapping of primary biliary cirrhosis and small duct primary sclerosing cholangitis: first case report. J Clin Med Res. 2012;4:429-433. [PMID: 23226177 DOI: 10.4021/jocmr1060w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
408 Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis 2012;2012:391567. [PMID: 23150824 DOI: 10.1155/2012/391567] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
409 Koutsoumpas AL, Kriese S, Rigopoulou EI. Popular and unpopular infectious agents linked to primary biliary cirrhosis. Auto Immun Highlights 2012;3:95-104. [PMID: 26000132 DOI: 10.1007/s13317-012-0039-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
410 Kempinska-Podhorodecka A, Shums Z, Wasilewicz M, Wunsch E, Milkiewicz M, Bogdanos DP, Norman GL, Milkiewicz P. TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis. Clin Dev Immunol 2012;2012:487521. [PMID: 23125866 DOI: 10.1155/2012/487521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
411 Milkiewicz M, Caballería L, Smyk DS, Milkiewicz P. Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. Auto Immun Highlights 2012;3:105-12. [PMID: 26000133 DOI: 10.1007/s13317-012-0038-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
412 Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, Nakamura H, Komori A, Nakamuta M, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Onji M, Kaneko S, Honda M, Yamagiwa S, Nakao K, Ichida T, Takikawa H, Seike M, Umemura T, Ueno Y, Sakisaka S, Kikuchi K, Ebinuma H, Yamashiki N, Tamura S, Sugawara Y, Mori A, Yagi S, Shirabe K, Taketomi A, Arai K, Monoe K, Ichikawa T, Taniai M, Miyake Y, Kumagi T, Abe M, Yoshizawa K, Joshita S, Shimoda S, Honda K, Takahashi H, Hirano K, Takeyama Y, Harada K, Migita K, Ito M, Yatsuhashi H, Fukushima N, Ota H, Komatsu T, Saoshiro T, Ishida J, Kouno H, Kouno H, Yagura M, Kobayashi M, Muro T, Masaki N, Hirata K, Watanabe Y, Nakamura Y, Shimada M, Hirashima N, Komeda T, Sugi K, Koga M, Ario K, Takesaki E, Maehara Y, Uemoto S, Kokudo N, Tsubouchi H, Mizokami M, Nakanuma Y, Tokunaga K, Ishibashi H. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 2012;91:721-8. [PMID: 23000144 DOI: 10.1016/j.ajhg.2012.08.010] [Cited by in Crossref: 194] [Cited by in F6Publishing: 167] [Article Influence: 17.6] [Reference Citation Analysis]
413 Ayyala US, Padilla ML. Diagnosis and treatment of hepatic sarcoidosis. Curr Treat Options Gastroenterol. 2006;9:475-483. [PMID: 17081481 DOI: 10.1007/s11938-006-0004-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
414 Smyk D, Rigopoulou EI, Zen Y, Abeles RD, Billinis C, Pares A, Bogdanos DP. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? World J Gastroenterol 2012; 18(35): 4855-4865 [PMID: 23002357 DOI: 10.3748/wjg.v18.i35.4855] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
415 Folci M, Meda F, Gershwin ME, Selmi C. Cutting-edge issues in primary biliary cirrhosis. Clin Rev Allergy Immunol 2012;42:342-54. [PMID: 21243445 DOI: 10.1007/s12016-011-8253-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
416 Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, Ducker SJ, Day DB, Heneghan MA, Neuberger JM, Donaldson PT, Bathgate AJ, Burroughs A, Davies MH, Jones DE, Alexander GJ, Barrett JC, Sandford RN, Anderson CA; UK Primary Biliary Cirrhosis (PBC) Consortium., Wellcome Trust Case Control Consortium 3. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet 2012;44:1137-41. [PMID: 22961000 DOI: 10.1038/ng.2395] [Cited by in Crossref: 210] [Cited by in F6Publishing: 214] [Article Influence: 19.1] [Reference Citation Analysis]
417 Greer JM, McCombe PA. The role of epigenetic mechanisms and processes in autoimmune disorders. Biologics 2012;6:307-27. [PMID: 23055689 DOI: 10.2147/BTT.S24067] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
418 Liu X, Hu Z, Deng A, Zhong R. Decreased miR-302e expression in monocytes of patients with primary biliary cirrhosis and its significance. Academic Journal of Second Military Medical University 2012;32:160-164. [DOI: 10.3724/sp.j.1008.2012.00160] [Reference Citation Analysis]
419 Smyk D, Rigopoulou EI, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity and environment: am I at risk? Clin Rev Allergy Immunol. 2012;42:199-212. [PMID: 21337133 DOI: 10.1007/s12016-011-8259-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
420 Invernizzi P, Alessio MG, Smyk DS, Lleo A, Sonzogni A, Fabris L, Candusso M, Bogdanos DP, Iorio R, Torre G. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol 2012;12:92. [PMID: 22816667 DOI: 10.1186/1471-230X-12-92] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
421 Gautier M, Desplat-jégo S. Dépistage au laboratoire d’immunologie d’une forme sévère de cirrhose biliaire primitive. Revue Francophone des Laboratoires 2012;2012:91-93. [DOI: 10.1016/s1773-035x(12)71623-4] [Reference Citation Analysis]
422 You Z, Wang Q, Bian Z, Liu Y, Han X, Peng Y, Shen L, Chen X, Qiu D, Selmi C, Gershwin ME, Ma X. The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun 2012;39:216-21. [PMID: 22727562 DOI: 10.1016/j.jaut.2012.05.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
423 Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PS. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol. 2012;168:279-284. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
424 Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PS. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol. 2012;168:279-284. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
425 Yang CY, Leung PS, Yang GX, Kenny TP, Zhang W, Coppel R, Norman GL, Ansari AA, Mackay IR, Worman HJ. Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent. Clin Exp Immunol. 2012;168:261-267. [PMID: 22519587 DOI: 10.1111/j.1365-2249.2012.04577.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
426 Zhang T, Baehr W, Fu Y. Chemical chaperone TUDCA preserves cone photoreceptors in a mouse model of Leber congenital amaurosis. Invest Ophthalmol Vis Sci 2012;53:3349-56. [PMID: 22531707 DOI: 10.1167/iovs.12-9851] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
427 Chen Y, Guo G, Guo S, Shimoda S, Shroyer KR, Tang Y, Wu Y. Intracellular B7-H4 suppresses bile duct epithelial cell apoptosis in human primary biliary cirrhosis. Inflammation 2011;34:688-97. [PMID: 21120594 DOI: 10.1007/s10753-010-9280-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
428 Hu B, Allina J, Bai J, Kesar V, Odin JA. Catalase and estradiol inhibit mitochondrial protein S-glutathionylation. Mol Cell Biochem 2012;367:51-8. [PMID: 22661379 DOI: 10.1007/s11010-012-1318-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
429 Haruta I, Kikuchi K, Nakamura M, Hirota K, Kato H, Miyakawa H, Shibata N, Miyake Y, Hashimoto E, Shiratori K, Yagi J. Involvement of commensal bacteria may lead to dysregulated inflammatory and autoimmune responses in a mouse model for chronic nonsuppurative destructive cholangitis. J Clin Immunol 2012;32:1026-37. [PMID: 22661269 DOI: 10.1007/s10875-012-9712-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
430 Yarnell E. Primary Biliary Cirrhosis. Alternative and Complementary Therapies 2012;18:148-151. [DOI: 10.1089/act.2012.18303] [Reference Citation Analysis]
431 Hu CJ, Song G, Huang W, Liu GZ, Deng CW, Zeng HP, Wang L, Zhang FC, Zhang X, Jeong JS. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012;11:669-680. [PMID: 22647870 DOI: 10.1074/mcp.m111.015529] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
432 Smyk DS, Rigopoulou EI, Pares A, Billinis C, Burroughs AK, Muratori L, Invernizzi P, Bogdanos DP. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol. 2012;2012:610504. [PMID: 22693524 DOI: 10.1155/2012/610504] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
433 Kempińska-Podhorecka A, Wunsch E, Jarowicz T, Raszeja-Wyszomirska J, Loniewska B, Kaczmarczyk M, Milkiewicz M, Milkiewicz P. Vitamin d receptor polymorphisms predispose to primary biliary cirrhosis and severity of the disease in polish population. Gastroenterol Res Pract 2012;2012:408723. [PMID: 22690210 DOI: 10.1155/2012/408723] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
434 Rigopoulou EI, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, Bogdanos DP. Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol 2012;2012:987471. [PMID: 22693505 DOI: 10.1155/2012/987471] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
435 Jin Q, Moritoki Y, Lleo A, Tsuneyama K, Invernizzi P, Moritoki H, Kikuchi K, Lian ZX, Hirschfield GM, Ansari AA, Coppel RL, Gershwin ME, Niu J. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012;55:1495-506. [PMID: 22135136 DOI: 10.1002/hep.25511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
436 Alempijevic T, Sokic-Milutinovic A, Pavlovic Markovic A, Jesic-Vukicevic R, Milicic B, Macut D, Popovic D, Tomic D. Assessment of metabolic syndrome in patients with primary biliary cirrhosis. Wien Klin Wochenschr 2012;124:251-5. [PMID: 22531844 DOI: 10.1007/s00508-012-0162-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
437 Qin B, Liang Y, Yang Z, Zhong R. Scientific publications on primary biliary cirrhosis from 2000 through 2010: an 11-year survey of the literature. PLoS One 2012;7:e35366. [PMID: 22509409 DOI: 10.1371/journal.pone.0035366] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
438 Beuers U. Cholestatic and Autoimmune Liver Disease. Medical Care of the Liver Transplant Patient 2012. [DOI: 10.1002/9781444398441.ch10] [Reference Citation Analysis]
439 Han XF, Wang QX, Liu Y, You ZR, Bian ZL, Qiu DK, Ma X. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis 2012;13:219-24. [PMID: 22435507 DOI: 10.1111/j.1751-2980.2012.00574.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
440 Duarte-Rey C, Bogdanos D, Yang CY, Roberts K, Leung PS, Anaya JM, Worman HJ, Gershwin ME. Primary biliary cirrhosis and the nuclear pore complex. Autoimmun Rev. 2012;11:898-902. [PMID: 22487189 DOI: 10.1016/j.autrev.2012.03.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
441 Kim KA, Jeong SH. The diagnosis and treatment of primary biliary cirrhosis. Korean J Hepatol. 2011;17:173-179. [PMID: 22102382 DOI: 10.3350/kjhep.2011.17.3.173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
442 Takahashi T, Miura T, Nakamura J, Yamada S, Miura T, Yanagi M, Matsuda Y, Usuda H, Emura I, Tsuneyama K, He XS, Gershwin ME. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology 2012;55:846-55. [PMID: 22031474 DOI: 10.1002/hep.24757] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
443 Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, Yang GX, Nakatani T, Vierling J, Lindor K, Gershwin ME, Bowlus CL. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012;55:512-21. [PMID: 22006563 DOI: 10.1002/hep.24748] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 9.9] [Reference Citation Analysis]
444 Umemura T, Joshita S, Ichijo T, Yoshizawa K, Katsuyama Y, Tanaka E, Ota M; Shinshu PBC Study Group. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology 2012;55:506-11. [PMID: 21953406 DOI: 10.1002/hep.24705] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
445 Smyk D, Rigopoulou EI, Bizzaro N, Bogdanos DP. Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. Auto Immun Highlights. 2013;4:1-9. [PMID: 26000137 DOI: 10.1007/s13317-011-0027-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
446 Bogdanos DP. Confirmation of the Diagnosis: Interpreting the Serology. Autoimmune Hepatitis 2012. [DOI: 10.1007/978-1-60761-569-9_4] [Reference Citation Analysis]
447 Sinakos E, Abbas G, Jorgensen RA, Lindor KD. Serum lipids in primary sclerosing cholangitis. Dig Liver Dis 2012;44:44-8. [PMID: 21890438 DOI: 10.1016/j.dld.2011.07.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
448 Tang Y, Zhang Y, You L, Bao W, Wang H, Yang J, Hu X. Human umbilical cord blood-derived mononuclear cell transplantation for umbilical hernia and hepatic hydrothorax in primary biliary cirrhosis. SCD 2012;02:31-35. [DOI: 10.4236/scd.2012.22005] [Reference Citation Analysis]
449 Kim K. Management of Primary Biliary Cirrhosis. Korean J Med 2012;82:32. [DOI: 10.3904/kjm.2012.82.1.32] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
450 Lleo A, Liao J, Invernizzi P, Zhao M, Bernuzzi F, Ma L, Lanzi G, Ansari AA, Coppel RL, Zhang P, Li Y, Zhou Z, Lu Q, Gershwin ME. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012;55:153-60. [PMID: 21898485 DOI: 10.1002/hep.24630] [Cited by in Crossref: 97] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
451 Onji M, Al-mahtab M, Mohammad Fazle Akbar S, Chen S, Abe M, Yoshida O, Ikeda Y, Hiasa Y. Suppression of Inflammatory Mucosal Milieu by Administration of Regulatory Dendritic Cells in an Animal Model of Primary Biliary Cirrhosis. Euroasian Journal of Hepato-Gastroenterology 2012;2:30-4. [DOI: 10.5005/jp-journals-10018-1028] [Reference Citation Analysis]
452 Boberg KM. Managing the Patient with Features of Overlapping Autoimmune Liver Disease. Autoimmune Hepatitis 2012. [DOI: 10.1007/978-1-60761-569-9_12] [Reference Citation Analysis]
453 Smyk DS, Bogdanos DP, Pares A, Liaskos C, Billinis C, Burroughs AK, Rigopoulou EI. Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature. Tuberculosis Research and Treatment 2012;2012:1-10. [DOI: 10.1155/2012/218183] [Reference Citation Analysis]
454 James SP. Primary Biliary Cirrhosis. Schiff's Diseases of the Liver 2011. [DOI: 10.1002/9781119950509.ch21] [Reference Citation Analysis]
455 Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol 2011;2011:976427. [PMID: 22187566 DOI: 10.1155/2011/976427] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
456 Smyk DS, Rigopoulou EI, Lleo A, Abeles RD, Mavropoulos A, Billinis C, Invernizzi P, Bogdanos DP. Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. Immun Ageing 2011;8:12. [PMID: 22136162 DOI: 10.1186/1742-4933-8-12] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
457 Kubo S, Iwata S, Saito K, Tanaka Y. Efficacité de l’étanercept dans une cirrhose biliaire primitive associée à une polyarthrite rhumatoïde. Revue du Rhumatisme 2011;78:589-590. [DOI: 10.1016/j.rhum.2011.04.012] [Reference Citation Analysis]
458 Jain P, Jha AK, Pokharna R, Sharma SS, Nepalia S. Hepatocellular carcinoma in a case of primary biliary cirrhosis. Clinical and Experimental Medical Journal 2011;5:259-261. [DOI: 10.1556/cemed.5.2011.4.10] [Reference Citation Analysis]
459 McNally RJ, James PW, Ducker S, James OF. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology 2011;54:2099-103. [PMID: 21826693 DOI: 10.1002/hep.24597] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
460 Ambrosini YM, Yang GX, Zhang W, Tsuda M, Shu S, Tsuneyama K, Leung PS, Ansari AA, Coppel RL, Gershwin ME. The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol 2011;166:110-20. [PMID: 21910728 DOI: 10.1111/j.1365-2249.2011.04453.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
461 Hu C, Deng C, Song G, Zhang W, Zhang S, Li X, Li P, Zhang F, Li Y. Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis. Dig Dis Sci 2011;56:3357-63. [PMID: 21660486 DOI: 10.1007/s10620-011-1756-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
462 Polido-Pereira J, Rodrigues AM, Canhão H, Saraiva F, da Silva JA, Fonseca JE. Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review. Clin Rheumatol 2012;31:385-9. [PMID: 22042492 DOI: 10.1007/s10067-011-1879-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
463 Lodh M, Pradhan D, Mukherjee A. Primary Biliary Cirrhosis Presenting with Gastritis, Hyperlipidemia and Marked Weight Loss. Ind J Clin Biochem 2011;26:423-425. [DOI: 10.1007/s12291-011-0148-9] [Reference Citation Analysis]
464 Jones DE. Complications of cholestasis. Medicine 2011;39:605-6. [DOI: 10.1016/j.mpmed.2011.07.007] [Reference Citation Analysis]
465 Smyk DS, Mytilinaiou MG, Milkiewicz P, Rigopoulou EI, Invernizzi P, Bogdanos DP. Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Auto Immun Highlights 2012;3:1-9. [PMID: 26000122 DOI: 10.1007/s13317-011-0023-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
466 Leung J, Bonis PA, Kaplan MM. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2011;9:776-80. [PMID: 21699802 DOI: 10.1016/j.cgh.2011.05.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
467 Zhao DT, Liao HY, Liu YM, Zhao Y, Feng X, Yan HP. Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients. Dig Dis Sci 2011;56:2750-7. [PMID: 21409375 DOI: 10.1007/s10620-011-1661-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
468 García-sabina A, Rabuñal Rey R, Martínez-pacheco R. Review of Use of Drugs for Conditions Not Included in Product Characteristics. Farmacia Hospitalaria (English Edition) 2011;35:264-277. [DOI: 10.1016/j.farmae.2010.06.006] [Reference Citation Analysis]
469 García-sabina A, Rabuñal Rey R, Martínez-pacheco R. Revisión sobre el uso de medicamentos en condiciones no incluidas en su ficha técnica. Farmacia Hospitalaria 2011;35:264-77. [DOI: 10.1016/j.farma.2010.06.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
470 Berg PA. The role of the innate immune recognition system in the pathogenesis of primary biliary cirrhosis: a conceptual view. Liver Int 2011;31:920-31. [PMID: 21733082 DOI: 10.1111/j.1478-3231.2011.02457.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
471 Naiyanetr P, Butler JD, Meng L, Pfeiff J, Kenny TP, Guggenheim KG, Reiger R, Lam K, Kurth MJ, Ansari AA. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J Autoimmun. 2011;37:209-216. [PMID: 21763105 DOI: 10.1016/j.jaut.2011.06.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
472 Selmi C, Maria Papini A, Pugliese P, Claudia Alcaro M, Gershwin ME. Environmental pathways to autoimmune diseases: the cases of primary biliary cirrhosis and multiple sclerosis. Arch Med Sci. 2011;7:368-380. [PMID: 22295019 DOI: 10.5114/aoms.2011.23398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
473 Niaz SK, Haqqi SA. Cholestatic liver diseases: Are liver transplant criteria different? Indian Journal of Transplantation 2011;5:61-65. [DOI: 10.1016/s2212-0017(11)60072-5] [Reference Citation Analysis]
474 Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, Yang GX, Yang CY, Coppel RL, Ansari AA, Cuebas DA, Worman HJ, Invernizzi P, Gores GJ, Norman G, He XS, Gershwin ME. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology 2011;54:196-203. [PMID: 21488079 DOI: 10.1002/hep.24355] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
475 Yanagisawa N, Haruta I, Kikuchi K, Shibata N, Yagi J. Are dysregulated inflammatory responses to commensal bacteria involved in the pathogenesis of hepatobiliary-pancreatic autoimmune disease? An analysis using mice models of primary biliary cirrhosis and autoimmune pancreatitis. ISRN Gastroenterol 2011;2011:513514. [PMID: 21991516 DOI: 10.5402/2011/513514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
476 Lee SA, Belyaeva OV, Kedishvili NY. Evidence that proteosome inhibitors and chemical chaperones can rescue the activity of retinol dehydrogenase 12 mutant T49M. Chem Biol Interact 2011;191:55-9. [PMID: 21232531 DOI: 10.1016/j.cbi.2011.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
477 Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, Todd JA, Peterson LB, Savage PB, Wills-Karp M. Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity. J Immunol. 2011;187:337-349. [PMID: 21613619 DOI: 10.4049/jimmunol.1003525] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
478 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2011. [DOI: 10.1002/14651858.cd009145] [Reference Citation Analysis]
479 Smyk D, Cholongitas E, Kriese S, Rigopoulou EI, Bogdanos DP. Primary biliary cirrhosis: family stories. Autoimmune Dis. 2011;2011:189585. [PMID: 21687641 DOI: 10.4061/2011/189585] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 1.1] [Reference Citation Analysis]
480 Inamine T, Nakamura M, Kawauchi A, Shirakawa Y, Hashiguchi H, Aiba Y, Taketomi A, Shirabe K, Nakamuta M, Hayashi S, Saoshiro T, Komori A, Yatsuhashi H, Kondo S, Omagari K, Maehara Y, Ishibashi H, Tsukamoto K; PBC Study Group in NHOSLJ. A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 2011;46:676-86. [PMID: 21116829 DOI: 10.1007/s00535-010-0351-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
481 Zhao J, Zhao S, Zhou G, Liang L, Guo X, Mao P, Zhou X, Wang H, Nan Y, Xu D, Yu J. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis. Scand J Gastroenterol 2011;46:485-94. [PMID: 21275501 DOI: 10.3109/00365521.2010.539624] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
482 Shimoda S, Harada K, Niiro H, Shirabe K, Taketomi A, Maehara Y, Tsuneyama K, Nakanuma Y, Leung P, Ansari AA, Gershwin ME, Akashi K. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011;53:1270-81. [PMID: 21400555 DOI: 10.1002/hep.24194] [Cited by in Crossref: 93] [Cited by in F6Publishing: 93] [Article Influence: 7.8] [Reference Citation Analysis]
483 Miura R, Tanaka A, Takikawa H. Urinary bile acid sulfate levels in patients with primary biliary cirrhosis. Hepatol Res 2011;41:358-63. [PMID: 21348908 DOI: 10.1111/j.1872-034X.2011.00779.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
484 Penz-Österreicher M, Österreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol 2011;25:245-58. [PMID: 21497742 DOI: 10.1016/j.bpg.2011.02.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
485 Smyk D, Grammatikopoulos T, Daponte A, Rigopoulou EI, Bogdanos DP. Fetomaternal alloimmunity as a cause of liver disease. Auto Immun Highlights 2011;2:21-8. [PMID: 26000116 DOI: 10.1007/s13317-011-0019-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
486 Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, Heneghan MA, Neuberger JM, Donaldson PT, Day DB. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43:329-332. [PMID: 21399635 DOI: 10.1038/ng.789] [Cited by in Crossref: 368] [Cited by in F6Publishing: 390] [Article Influence: 30.7] [Reference Citation Analysis]
487 El-Masry M, Puig CA, Saab S. Recurrence of non-viral liver disease after orthotopic liver transplantation. Liver Int 2011;31:291-302. [PMID: 21281429 DOI: 10.1111/j.1478-3231.2010.02434.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
488 Wong GL, Wong VW, Chim AM, Yiu KK, Chu SH, Li MK, Chan HL. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011;26:300-5. [PMID: 21261720 DOI: 10.1111/j.1440-1746.2010.06510.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 8.8] [Reference Citation Analysis]
489 Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E; International Autoimmune Hepatitis Group. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-85. [PMID: 21067838 DOI: 10.1016/j.jhep.2010.09.002] [Cited by in Crossref: 347] [Cited by in F6Publishing: 357] [Article Influence: 28.9] [Reference Citation Analysis]
490 He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011;53:548-57. [PMID: 21274875 DOI: 10.1002/hep.24047] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
491 Miyake Y, Ikeda F, Takaki A, Nouso K, Yamamoto K. +49A/G polymorphism of cytotoxic T-lymphocyte antigen 4 gene in type 1 autoimmune hepatitis and primary biliary cirrhosis: A meta-analysis. Hepatol Res 2011;41:151-9. [PMID: 21269385 DOI: 10.1111/j.1872-034X.2010.00757.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
492 Mattner J. Genetic susceptibility to autoimmune liver disease. World J Hepatol 2011; 3(1): 1-7 [PMID: 21307981 DOI: 10.4254/wjh.v3.i1.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
493 Fragoulis GE, Skopouli FN, Selmi C, Gershwin ME. Liver Involvement in Sjögren’s Syndrome. Sjögren’s Syndrome 2011. [DOI: 10.1007/978-0-85729-947-5_17] [Reference Citation Analysis]
494 Ahmad J. Cases 1–26. Hepatology and Transplant Hepatology 2011. [DOI: 10.1007/978-1-4419-7085-5_1] [Reference Citation Analysis]
495 Pruritus and Neurocutaneous Dermatoses. Andrews' Diseases of the Skin 2011. [DOI: 10.1016/b978-1-4377-0314-6.00004-8] [Reference Citation Analysis]
496 Mayes MD, Assassi S. Sclerodactyly and Raynaud’s Phenomenon in a Patient Who Has Primary Biliary Cirrhosis. Case Studies in Systemic Sclerosis 2011. [DOI: 10.1007/978-0-85729-641-2_35] [Reference Citation Analysis]
497 Mazhar SM, Faria SC, Peterson MR, Sirlin CB. Cholestatic Hepatic Disorders. Abdominal Imaging 2011. [DOI: 10.1016/b978-1-4160-5449-8.00071-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
498 Hwang JY, Yoon H, Kang JS, Lee SA, Lee WJ, Lee K, Park JY. The Primary Biliary Cirrhosis Presenting with Raynaud's Disease and Digital Necrosis. J Rheum Dis 2011;18:50. [DOI: 10.4078/jrd.2011.18.1.50] [Reference Citation Analysis]
499 Kakar S. Primary Biliary Cirrhosis. Practical Hepatic Pathology: A Diagnostic Approach 2011. [DOI: 10.1016/b978-0-443-06803-4.00026-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
500 Selmi C, Gershwin ME. Primary Biliary Cirrhosis. Molecular Pathology Library 2011. [DOI: 10.1007/978-1-4419-7107-4_49] [Reference Citation Analysis]
501 Bhagavan N, Ha C. Case Studies and Enrichment References. Essentials of Medical Biochemistry 2011. [DOI: 10.1016/b978-0-12-095461-2.00038-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
502 Pilcher JM. Diffuse parenchymal liver disease. Clinical Ultrasound 2011. [DOI: 10.1016/b978-0-7020-3131-1.00008-0] [Reference Citation Analysis]
503 Lleo A, Shimoda S, Ishibashi H, Gershwin ME. Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. J Gastroenterol 2011;46 Suppl 1:29-38. [PMID: 20798971 DOI: 10.1007/s00535-010-0303-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
504 Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, Pesente F, Alessio MG, Tampoia M, Antico A, Platzgummer S, Porcelli B, Terzuoli L, Liguori M, Bassetti D, Brusca I, Almasio PL, Tarantino G, Bonaguri C, Agostinis P, Bredi E, Tozzoli R, Invernizzi P, Selmi C. Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. Clinic Rev Allerg Immunol 2012;42:288-97. [DOI: 10.1007/s12016-010-8234-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 4.0] [Reference Citation Analysis]
505 Douguchi J, Hashiguchi A, Sakamoto M. Construction of human monoclonal single-chain Fv antibodies against small-cell lung cancer by phage display libraries derived from cell-immunized SCID mice engrafted with human peripheral blood lymphocytes. Proteomics Clin Appl 2009;3:1265-72. [PMID: 21136949 DOI: 10.1002/prca.200900060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
506 Sasaki M, Nakanuma Y. Biliary epithelial apoptosis, autophagy, and senescence in primary biliary cirrhosis. Hepat Res Treat. 2010;2010:205128. [PMID: 21152179 DOI: 10.1155/2010/205128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
507 Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010;139:1481-96. [PMID: 20849855 DOI: 10.1053/j.gastro.2010.09.004] [Cited by in Crossref: 184] [Cited by in F6Publishing: 185] [Article Influence: 14.2] [Reference Citation Analysis]
508 Kaplan MM, Bonder A, Ruthazer R, Bonis PA. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci 2010;55:3207-17. [PMID: 20559727 DOI: 10.1007/s10620-010-1291-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
509 Voumvouraki A, Koulentaki M, Tzardi M, Sfakianaki O, Manousou P, Notas G, Kouroumalis E. Increased ΤGF-β3 in primary biliary cirrhosis: An abnormality related to pathogenesis? World J Gastroenterol 2010; 16(40): 5057-5064 [PMID: 20976842 DOI: 10.3748/wjg.v16.i40.5057] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
510 Selmi C, Mackay IR, Gershwin ME. The autoimmunity of primary biliary cirrhosis and the clonal selection theory. Immunol Cell Biol 2011;89:70-80. [PMID: 20975735 DOI: 10.1038/icb.2010.126] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
511 Selmi C, Affronti A, Ferrari L, Invernizzi P. Immune-mediated bile duct injury: The case of primary biliary cirrhosis. World J Gastrointest Pathophysiol 2010; 1(4): 118-128 [PMID: 21607152 DOI: 10.4291/wjgp.v1.i4.118] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
512 Montali L, Tanaka A, Riva P, Takahashi H, Cocchi C, Ueno Y, Miglioretti M, Takikawa H, Vecchio L, Frigerio A, Bianchi I, Jorgensen R, Lindor KD, Podda M, Invernizzi P; Italian-Japanese PBC Study Group. A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. Dig Liver Dis 2010;42:718-23. [PMID: 20163995 DOI: 10.1016/j.dld.2010.01.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
513 Nguyen DL, Juran BD, Lazaridis KN. Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol 2010;24:647-54. [PMID: 20955967 DOI: 10.1016/j.bpg.2010.07.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
514 Bal C, Chawla M. Hyperthyroidism and jaundice. Indian J Nucl Med 2010;25:131-4. [PMID: 21713219 DOI: 10.4103/0972-3919.78244] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
515 Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, Heathcote EJ, Hirschfield GM. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105:2186-94. [PMID: 20502446 DOI: 10.1038/ajg.2010.216] [Cited by in Crossref: 237] [Cited by in F6Publishing: 215] [Article Influence: 18.2] [Reference Citation Analysis]
516 Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Tarantino L, Perrella A, Perrella O, De Chiara G, Panico L, De Stefano N, Lepore M, Mariolina, Vecchione R. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol 2010;45:1053-62. [PMID: 20393861 DOI: 10.1007/s00535-010-0249-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
517 Papp M, Norman GL, Vitalis Z, Tornai I, Altorjay I, Foldi I, Udvardy M, Shums Z, Dinya T, Orosz P. Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity? PLoS One. 2010;5:e12957. [PMID: 20886039 DOI: 10.1371/journal.pone.0012957] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
518 Zein CO, Lindor KD. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep. 2010;12:13-22. [PMID: 20425480 DOI: 10.1007/s11894-009-0079-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
519 Xiong Y, Zhong R. Non-elevated cardiovascular risk in patients with primary biliary cirrhosis and hypercholesterolemia. Academic Journal of Second Military Medical University 2010;30:904-906. [DOI: 10.3724/sp.j.1008.2010.00904] [Reference Citation Analysis]
520 Hirschfield GM, Heathcote EJ. Primary Biliary Cirrhosis. Evidence‐Based Gastroenterology and Hepatology 2010. [DOI: 10.1002/9781444314403.ch32] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
521 Li WX, Gou JF, Yan X, Shi CR, Zhang AP, Sui JH. Chlorambucil for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008714] [Reference Citation Analysis]
522 Liu H, Liu Y, Wang L, Xu D, Lin B, Zhong R, Gong S, Podda M, Invernizzi P. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol. 2010;10:100. [PMID: 20815889 DOI: 10.1186/1471-230x-10-100] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
523 Yanagisawa M, Takagi H, Takahashi H, Uehara M, Otsuka T, Yuasa K, Hosonuma K, Mori M. Familial clustering and genetic background of primary biliary cirrhosis in Japan. Dig Dis Sci 2010;55:2651-8. [PMID: 20012485 DOI: 10.1007/s10620-009-1057-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
524 Joshita S, Umemura T, Yoshizawa K, Katsuyama Y, Tanaka E, Nakamura M, Ishibashi H, Ota M; Shinshu PBC Study Group. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol 2010;53:537-41. [PMID: 20557968 DOI: 10.1016/j.jhep.2010.03.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
525 Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J, Ansari AA, Coppel RL, Worman HJ, Gores GJ, Gershwin ME. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 2010;52:987-98. [PMID: 20568301 DOI: 10.1002/hep.23783] [Cited by in Crossref: 157] [Cited by in F6Publishing: 147] [Article Influence: 12.1] [Reference Citation Analysis]
526 Altorjay I, Vitalis Z, Tornai I, Palatka K, Kacska S, Farkas G, Udvardy M, Harsfalvi J, Dinya T, Orosz P, Lombay B Jr, Par G, Par A, Csak T, Osztovits J, Szalay F, Csepregi A, Lakatos PL, Papp M. Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis. J Hepatol 2010;53:484-91. [PMID: 20605050 DOI: 10.1016/j.jhep.2010.03.028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
527 Wang D, Zhang H, Liang J, Gu Z, Zhou Q, Fan X, Hou Y, Sun L. CD4+ CD25+ but not CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis. Cell Mol Immunol. 2010;7:485-490. [PMID: 20729906 DOI: 10.1038/cmi.2010.40] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
528 Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us? World J Gastroenterol 2010; 16(29): 3616-3629 [PMID: 20677333 DOI: 10.3748/wjg.v16.i29.3616] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
529 Wang D, Zhang H, Liang J, Gu Z, Ma X, Huang J, Lin J, Hou Y, Lu L, Sun L. Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyI: C-induced primary biliary cirrhosis mouse model. Clin Exp Med. 2011;11:25-32. [PMID: 20661620 DOI: 10.1007/s10238-010-0105-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
530 Gatselis NK, Zachou K, Dalekos GN. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. Gastroenterol Res Pract 2010;2010:121620. [PMID: 20706542 DOI: 10.1155/2010/121620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
531 Juran BD, Lazaridis KN. Update on the genetics and genomics of PBC. J Autoimmun. 2010;35:181-187. [PMID: 20638243 DOI: 10.1016/j.jaut.2010.06.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
532 Bernuzzi F, Fenoglio D, Battaglia F, Fravega M, Gershwin ME, Indiveri F, Ansari AA, Podda M, Invernizzi P, Filaci G. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun. 2010;35:176-180. [PMID: 20638239 DOI: 10.1016/j.jaut.2010.06.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
533 Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol 2010;24:225-31. [PMID: 20431809 DOI: 10.1155/2010/431913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
534 Koyabu M, Uchida K, Miyoshi H, Sakaguchi Y, Fukui T, Ikeda H, Takaoka M, Hirohara J, Nishio A, Uemura Y, Uemoto S, Okazaki K. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol 2010;45:732-41. [PMID: 20087609 DOI: 10.1007/s00535-010-0199-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 5.5] [Reference Citation Analysis]
535 Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Liu X, Heathcote EJ, Hirschfield GM, Siminovitch KA, Lazaridis KN. Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology 2010;52:223-9. [PMID: 20578265 DOI: 10.1002/hep.23667] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
536 Zhang W, Tsuda M, Yang GX, Tsuneyama K, Rong G, Ridgway WM, Ansari AA, Flavell RA, Coppel RL, Lian ZX, Gershwin ME. Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology 2010;52:215-22. [PMID: 20578264 DOI: 10.1002/hep.23664] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
537 Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010;52:349-59. [PMID: 20578151 DOI: 10.1002/hep.23637] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
538 Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010;55:2086-8. [PMID: 19795210 DOI: 10.1007/s10620-009-0988-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
539 Rashtak S, Marietta EV, Murray JA. Celiac sprue: a unique autoimmune disorder. Expert Rev Clin Immunol 2009;5:593-604. [PMID: 20477645 DOI: 10.1586/eci.09.30] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
540 Huss S, Schmitz J, Goltz D, Fischer HP, Büttner R, Weiskirchen R. Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis. Fibrogenesis Tissue Repair 2010;3:10. [PMID: 20565730 DOI: 10.1186/1755-1536-3-10] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
541 Mancinelli R, Onori P, DeMorrow S, Francis H, Glaser S, Franchitto A, Carpino G, Alpini G, Gaudio E. Role of sex hormones in the modulation of cholangiocyte function. World J Gastrointest Pathophysiol 2010; 1(2): 50-62 [PMID: 21607142 DOI: 10.4291/wjgp.v1.i2.50] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
542 Invernizzi P, Selmi C, Gershwin ME. Update on primary biliary cirrhosis. Dig Liver Dis 2010;42:401-8. [PMID: 20359968 DOI: 10.1016/j.dld.2010.02.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
543 Abbas G, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2010;7:313-9. [PMID: 20458334 DOI: 10.1038/nrgastro.2010.62] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
544 Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010;8:530-4. [PMID: 20304098 DOI: 10.1016/j.cgh.2010.03.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 5.8] [Reference Citation Analysis]
545 Spagnolo P, Zeuzem S, Richeldi L, du Bois RM. The complex interrelationships between chronic lung and liver disease: a review. J Viral Hepat 2010;17:381-90. [PMID: 20384964 DOI: 10.1111/j.1365-2893.2010.01307.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
546 Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM. Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010;12:R47. [PMID: 20302639 DOI: 10.1186/ar2958] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
547 Chan CW, Tsochatzis EA, Carpenter JR, Rigamonti C, Gunsar F, Burroughs AK. Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. Aliment Pharmacol Ther 2010;31:573-82. [PMID: 20003096 DOI: 10.1111/j.1365-2036.2009.04215.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
548 Shimoda S, Harada K, Niiro H, Taketomi A, Maehara Y, Tsuneyama K, Kikuchi K, Nakanuma Y, Mackay IR, Gershwin ME, Akashi K. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology 2010;51:567-75. [PMID: 19908209 DOI: 10.1002/hep.23318] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 6.3] [Reference Citation Analysis]
549 Selmi C, Torok NJ, Affronti A, Gershwin ME. Genomic variants associated with primary biliary cirrhosis. Genome Med 2010;2:5. [PMID: 20193050 DOI: 10.1186/gm126] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
550 Crawford JM, Liu C. Liver and Biliary Tract. Robbins and Cotran Pathologic Basis of Disease 2010. [DOI: 10.1016/b978-1-4377-0792-2.50023-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
551 Krok K, Koteish A. Liver Disease in Women. Principles of Gender-Specific Medicine 2010. [DOI: 10.1016/b978-0-12-374271-1.00031-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
552 Holt M, Ju C. The Adaptive Immune System and Liver Toxicity. Comprehensive Toxicology 2010. [DOI: 10.1016/b978-0-08-046884-6.01030-7] [Reference Citation Analysis]
553 GLUCOCORTICOIDS AND DISEASE – MODIFYING ANTIRHEUMATIC DRUGS. Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs 2010. [DOI: 10.1016/b978-0-444-53273-2.50007-9] [Reference Citation Analysis]
554 Friedrich-Rust M, Müller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Poynard T, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J Clin Gastroenterol 2010;44:58-65. [PMID: 19581812 DOI: 10.1097/MCG.0b013e3181a84b8d] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 5.1] [Reference Citation Analysis]
555 Lefkowitch JH. Biliary Disease. Scheuer's Liver Biopsy Interpretation 2010. [DOI: 10.1016/b978-0-7020-3410-7.00011-3] [Reference Citation Analysis]
556 Dancygier H. Primary Biliary Cirrhosis. Clinical Hepatology 2010. [DOI: 10.1007/978-3-642-04519-6_19] [Reference Citation Analysis]
557 Zein CO. Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Other Cholestatic Liver Diseases. Current Clinical Medicine 2010. [DOI: 10.1016/b978-1-4160-6643-9.00081-3] [Reference Citation Analysis]
558 Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, Quarneti C, Bianchi FB, Bloch DB, Muratori P. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 2010;105:125-31. [PMID: 19861957 DOI: 10.1038/ajg.2009.596] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 4.7] [Reference Citation Analysis]
559 Selmi C, Meda F, Kasangian A, Invernizzi P, Tian Z, Lian Z, Podda M, Gershwin ME. Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cell Mol Immunol 2010;7:1-10. [PMID: 20029462 DOI: 10.1038/cmi.2009.104] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
560 Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, Ueno Y, Dunn R, Kehry M, Coppel RL, Mackay IR, Gershwin ME. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology 2009;50:1893-903. [PMID: 19877182 DOI: 10.1002/hep.23238] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 5.2] [Reference Citation Analysis]
561 León VHP, Aldás EG. Síndrome de Reynolds. Piel 2009;24:539-541. [DOI: 10.1016/s0213-9251(09)73038-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
562 Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, Moritoki Y, Ansari AA, Okazaki K, Lian ZX, Coppel RL, Mackay IR, Gershwin ME. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 2009;50:1494-500. [PMID: 19676134 DOI: 10.1002/hep.23132] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 6.9] [Reference Citation Analysis]
563 Zhang W, Moritoki Y, Tsuneyama K, Yang GX, Ilan Y, Lian ZX, Gershwin ME. Beta-glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis. Clin Exp Immunol. 2009;157:359-364. [PMID: 19664143 DOI: 10.1111/j.1365-2249.2009.03971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
564 Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009;54:2242-6. [PMID: 19082890 DOI: 10.1007/s10620-008-0613-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
565 McNally RJ, Ducker S, James OF. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology 2009;50:1169-74. [PMID: 19711423 DOI: 10.1002/hep.23139] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
566 Su CW, Chan CC, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Tsay SH, Lee PC, Lee SD, Wu JC. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol 2009;43:876-83. [PMID: 19247208 DOI: 10.1097/MCG.0b013e31818980ac] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
567 Cavazza A, Caballería L, Floreani A, Farinati F, Bruguera M, Caroli D, Parés A. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009;50:1162-8. [PMID: 19585656 DOI: 10.1002/hep.23095] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 5.7] [Reference Citation Analysis]
568 Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009;39:865-73. [PMID: 19467021 DOI: 10.1111/j.1872-034X.2009.00527.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
569 Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, Manek N, Perry M, Ganesh D, Rahbar MH, Mayes MD. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009;36:2250-6. [PMID: 19723904 DOI: 10.3899/jrheum.090340] [Cited by in Crossref: 77] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
570 Tian Y, Wang C, Liu JX, Wang HH. Primary Biliary Cirrhosis-Related Autoimmune Hemolytic Anemia: Three Case Reports and Review of the Literature. Case Rep Gastroenterol 2009;3:240-7. [PMID: 21103282 DOI: 10.1159/000229189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
571 Zhong B, Strnad P, Selmi C, Invernizzi P, Tao GZ, Caleffi A, Chen M, Bianchi I, Podda M, Pietrangelo A, Gershwin ME, Omary MB. Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology 2009;50:546-54. [PMID: 19585610 DOI: 10.1002/hep.23041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
572 Kronenberg M, Kinjo Y. Innate-like recognition of microbes by invariant natural killer T cells. Curr Opin Immunol. 2009;21:391-396. [PMID: 19646850 DOI: 10.1016/j.coi.2009.07.002] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
573 Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31:283-307. [PMID: 19603170 DOI: 10.1007/s00281-009-0164-5] [Cited by in Crossref: 123] [Cited by in F6Publishing: 134] [Article Influence: 8.8] [Reference Citation Analysis]
574 Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Benedetti A. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009;58:990-7. [PMID: 18829977 DOI: 10.1136/gut.2008.150870] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
575 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 924] [Cited by in F6Publishing: 808] [Article Influence: 66.0] [Reference Citation Analysis]
576 Chuang YH, Lan RY, Gershwin ME. The immunopathology of human biliary cell epithelium. Semin Immunopathol. 2009;31:323-331. [PMID: 19533127 DOI: 10.1007/s00281-009-0172-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
577 Rodríguez Gil FJ, Martínez Crespo JJ, García Belmonte D, Nicolás de Prado I, de Prado Serrano R. [Jaundice in a patient treated with etanercept]. Gastroenterol Hepatol 2009;32:584-5. [PMID: 19523718 DOI: 10.1016/j.gastrohep.2009.02.007] [Reference Citation Analysis]
578 Silveira MG, Lindor KD. 38-Year-Old Woman With Abnormal Liver Enzymes and Hyperlipidemia. Mayo Clinic Proceedings 2009;84:551-554. [DOI: 10.4065/84.6.551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
579 Tanaka A, Nezu S, Uegaki S, Kikuchi K, Shibuya A, Miyakawa H, Takahashi S, Bianchi I, Zermiani P, Podda M, Ohira H, Invernizzi P, Takikawa H. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol 2009;50:1202-9. [PMID: 19376604 DOI: 10.1016/j.jhep.2009.01.015] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
580 Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Lazaridis KN. Common genetic variation and haplotypes of the anion exchanger SLC4A2 in primary biliary cirrhosis. Am J Gastroenterol 2009;104:1406-11. [PMID: 19491853 DOI: 10.1038/ajg.2009.103] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
581 Adorini L. Vitamin D receptor polymorphisms in primary biliary cirrhosis: a functional connection? J Hepatol 2009;50:1071-3. [PMID: 19398232 DOI: 10.1016/j.jhep.2009.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
582 Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360:2544-2555. [PMID: 19458352 DOI: 10.1056/nejmoa0810440] [Cited by in Crossref: 467] [Cited by in F6Publishing: 499] [Article Influence: 33.4] [Reference Citation Analysis]
583 Krok KL, Munoz SJ. Management of autoimmune and cholestatic liver disorders. Clin Liver Dis 2009;13:295-316. [PMID: 19442920 DOI: 10.1016/j.cld.2009.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
584 Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, Mao TK, Coppel RL, Ansari AA, Gershwin ME. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun. 2009;32:246-253. [PMID: 19345069 DOI: 10.1016/j.jaut.2009.02.022] [Cited by in Crossref: 152] [Cited by in F6Publishing: 166] [Article Influence: 10.9] [Reference Citation Analysis]
585 Bogdanos DP, Vergani D. Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol. 2009;36:30-39. [PMID: 18498061 DOI: 10.1007/s12016-008-8087-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
586 Rong G, Zhou Y, Xiong Y, Zhou L, Geng H, Jiang T, Zhu Y, Lu H, Zhang S, Wang P, Zhang B, Zhong R. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 2009;156:217-25. [PMID: 19302244 DOI: 10.1111/j.1365-2249.2009.03898.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 134] [Article Influence: 8.9] [Reference Citation Analysis]
587 Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, Gores GJ, Ansari AA, Van de Water J, Gershwin ME. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology 2009;49:871-9. [PMID: 19185000 DOI: 10.1002/hep.22736] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 11.4] [Reference Citation Analysis]
588 Moritoki Y, Zhang W, Tsuneyama K, Yoshida K, Wakabayashi K, Yang GX, Bowlus C, Ridgway WM, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Flavell RA, Gershwin ME, Lian ZX. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 2009;136:1037-47. [PMID: 19118554 DOI: 10.1053/j.gastro.2008.11.035] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
589 Alempijevic T, Krstic M, Jesic R, Jovanovic I, Milutinovic AS, Kovacevic N, Krstic S, Popovic D. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol 2009; 15(5): 591-594 [PMID: 19195061 DOI: 10.3748/wjg.15.591] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
590 Zhang W, Sharma R, Ju ST, He XS, Tao Y, Tsuneyama K, Tian Z, Lian ZX, Fu SM, Gershwin ME. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 2009;49:545-52. [PMID: 19065675 DOI: 10.1002/hep.22651] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
591 Beuers U, Bastiaansen BA. Clinical aspects of primary biliary cirrhosis. Chronic Inflammation of Liver and Gut 2009. [DOI: 10.1007/978-1-4020-9353-1_17] [Reference Citation Analysis]
592 Tanaka A, Takahashi H, Nezu S, Ueno Y, Kikuchi K, Shibuya A, Ohira H, Zeniya M, Montali L, Invernizzi P, Takikawa H. Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis. Kanzo 2009;50:51-59. [DOI: 10.2957/kanzo.50.51] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
593 Peakman M, Vergani D. Liver diseases. Basic and Clinical Immunology 2009. [DOI: 10.1016/b978-0-443-10082-6.50019-1] [Reference Citation Analysis]
594 Liver, biliary system and exocrine pancreas. General and Systematic Pathology 2009. [DOI: 10.1016/b978-0-443-06888-1.00016-x] [Reference Citation Analysis]
595 Parés A. Excellent long-term survival in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Bile Acid Biology and Therapeutic Actions 2009. [DOI: 10.1007/978-1-4020-9644-0_35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
596 Yoon BY, Song HY, Lee JH, Kim KA. A Case of Primary Biliary Cirrhosis in Association with an Overlap Syndrome of Systemic Sclerosis and Systemic Lupus Erythematosus. J Korean Rheum Assoc 2009;16:338. [DOI: 10.4078/jkra.2009.16.4.338] [Reference Citation Analysis]
597 Erkrankungen des Gastrointestinalsystems. Innere Medizin 2009. [DOI: 10.1016/b978-3-437-42831-9.10015-4] [Reference Citation Analysis]
598 Wakabayashi K, Yoshida K, Leung PS, Moritoki Y, Yang GX, Tsuneyama K, Lian ZX, Hibi T, Ansari AA, Wicker LS, Ridgway WM, Coppel RL, Mackay IR, Gershwin ME. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol. 2009;155:577-586. [PMID: 19094117 DOI: 10.1111/j.1365-2249.2008.03837.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
599 Invernizzi P, Selmi C, Poli F, Frison S, Floreani A, Alvaro D, Almasio P, Rosina F, Marzioni M, Fabris L, Muratori L, Qi L, Seldin MF, Gershwin ME, Podda M; Italian PBC Genetic Study Group. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology 2008;48:1906-12. [PMID: 19003916 DOI: 10.1002/hep.22567] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 6.5] [Reference Citation Analysis]
600 Nikkilä K, Nissinen MJ, Gylling H, Isoniemi H, Miettinen TA. Serum sterols in patients with primary biliary cirrhosis and acute liver failure before and after liver transplantation. J Hepatol 2008;49:936-45. [PMID: 18926587 DOI: 10.1016/j.jhep.2008.07.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
601 Poupon R, Ping C, Chrétien Y, Corpechot C, Chazouillères O, Simon T, Heath SC, Matsuda F, Poupon RE, Housset C, Barbu V. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008;49:1038-45. [PMID: 18930330 DOI: 10.1016/j.jhep.2008.07.027] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 6.7] [Reference Citation Analysis]
602 Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME. Immunology of primary biliary cirrhosis and primary sclerosing cholangitis. Pathogenesis and Clinical Practice in Gastroenterology. [DOI: 10.1007/978-1-4020-8767-7_19] [Reference Citation Analysis]
603 Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008;22:505-7. [PMID: 18478137 DOI: 10.1155/2008/969826] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
604 Ozcelik T. X chromosome inactivation and female predisposition to autoimmunity. Clin Rev Allergy Immunol 2008;34:348-51. [PMID: 18097773 DOI: 10.1007/s12016-007-8051-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
605 Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008;48:1149-56. [PMID: 18785621 DOI: 10.1002/hep.22458] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
606 Gotthardt D, Runz H, Keitel V, Fischer C, Flechtenmacher C, Wirtenberger M, Weiss KH, Imparato S, Braun A, Hemminki K, Stremmel W, Rüschendorf F, Stiehl A, Kubitz R, Burwinkel B, Schirmacher P, Knisely AS, Zschocke J, Sauer P. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008;48:1157-66. [PMID: 18781607 DOI: 10.1002/hep.22485] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 6.0] [Reference Citation Analysis]
607 Sprinzl MF, Galle PR. Differential diagnosis of human hepatitis. Comparative Hepatitis. [DOI: 10.1007/978-3-7643-8558-3_2] [Reference Citation Analysis]
608 Tamura S, Sugawara Y, Kaneko J, Togashi J, Matsui Y, Yamashiki N, Kokudo N, Makuuchi M. Recurrence of cholestatic liver disease after living donor liver transplantation. World J Gastroenterol 2008; 14(33): 5105-5109 [PMID: 18777585 DOI: 10.3748/wjg.14.5105] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
609 Oshitari T, Hata N, Yamamoto S. Endoplasmic reticulum stress and diabetic retinopathy. Vasc Health Risk Manag. 2008;4:115-122. [PMID: 18629365 DOI: 10.2147/vhrm.s2293] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
610 Oshitari T, Hata N, Yamamoto S. Endoplasmic reticulum stress and diabetic retinopathy. Vasc Health Risk Manag 2008;4:115-22. [PMID: 18629365 DOI: 10.2147/vhrm.2008.04.01.115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 59] [Article Influence: 2.0] [Reference Citation Analysis]
611 Ohishi Y, Nakamura M, Iio N, Higa S, Inayoshi M, Aiba Y, Komori A, Omagari K, Ishibashi H, Tsukamoto K. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology 2008;48:853-62. [PMID: 18671305 DOI: 10.1002/hep.22382] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
612 Wong GL, Wong VW, Choi PC, Chan AW, Chum RH, Chan HK, Lau KK, Chim AM, Yiu KK, Chan FK, Sung JJ, Chan HL. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008;6:1027-35. [PMID: 18456573 DOI: 10.1016/j.cgh.2008.02.038] [Cited by in Crossref: 119] [Cited by in F6Publishing: 98] [Article Influence: 7.9] [Reference Citation Analysis]
613 Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol 2008;49:466-73. [PMID: 18644655 DOI: 10.1016/j.jhep.2008.05.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
614 Selmi C, Zuin M, Gershwin ME. The unfinished business of primary biliary cirrhosis. J Hepatol 2008;49:451-60. [PMID: 18640737 DOI: 10.1016/j.jhep.2008.06.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
615 Tsikrikoni A, Rigopoulou EI, Zachou K, Liaskos C, Kyriakou D, Dalekos GN. Bone marrow findings in patients with autoimmune liver diseases. J Gastroenterol Hepatol 2008;23:e416-21. [PMID: 18205770 DOI: 10.1111/j.1440-1746.2008.05309.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
616 Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol Res 2008;38:745-61. [PMID: 18462376 DOI: 10.1111/j.1872-034X.2008.00366.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
617 Newton JL, Hollingsworth KG, Taylor R, El-Sharkawy AM, Khan ZU, Pearce R, Sutcliffe K, Okonkwo O, Davidson A, Burt J, Blamire AM, Jones D. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology 2008;48:541-9. [PMID: 18563843 DOI: 10.1002/hep.22371] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 6.7] [Reference Citation Analysis]
618 Luedde T, Heinrichsdorff J, de Lorenzi R, De Vos R, Roskams T, Pasparakis M. IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc Natl Acad Sci U S A 2008;105:9733-8. [PMID: 18606991 DOI: 10.1073/pnas.0800198105] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 4.6] [Reference Citation Analysis]
619 Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, Scanlon ST, Pendem K, Teyton L, Hart J, Ridgway WM, Wicker LS, Gershwin ME, Bendelac A. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008;3:304-15. [PMID: 18474357 DOI: 10.1016/j.chom.2008.03.009] [Cited by in Crossref: 171] [Cited by in F6Publishing: 180] [Article Influence: 11.4] [Reference Citation Analysis]
620 Nakajima A, Kurihara H, Yagita H, Okumura K, Nakano H. Mitochondrial Extrusion through the cytoplasmic vacuoles during cell death. J Biol Chem 2008;283:24128-35. [PMID: 18593703 DOI: 10.1074/jbc.M802996200] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
621 Sakly W, Jeddi M, Ghedira I. Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci 2008;53:1983-7. [PMID: 18049897 DOI: 10.1007/s10620-007-0092-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
622 Johanet C, Gaouar F, Salle A, Diemert B, Ballot E, Chazouillères O, Carrat F, Poupon R, Corpechot C. Évaluation de l'incidence de la cirrhose biliaire primitive en 2007 en France. Revue Francophone des Laboratoires 2008;2008:25-28. [DOI: 10.1016/s1773-035x(08)71574-0] [Reference Citation Analysis]
623 Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H Jr, Odin JA. Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis. Dig Dis Sci 2008;53:1988-93. [PMID: 18392679 DOI: 10.1007/s10620-007-0003-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
624 Qian C, Chen S, Yao D, Wu C, Jiang T, Ke J, Zhou Y, Gu M, Chen B, Deng A, Zhong R. Increased granulysin expression in peripheral blood cells of patients with primary biliary cirrhosis and its clinical implications. J Clin Immunol 2008;28:520-7. [PMID: 18584314 DOI: 10.1007/s10875-008-9207-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
625 Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3328-3337 [PMID: 18528930 DOI: 10.3748/wjg.14.3328] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
626 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
627 Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: Current diagnostic and clinical challenges. World J Gastroenterol 2008; 14(21): 3374-3387 [PMID: 18528935 DOI: 10.3748/wjg.14.3374] [Cited by in CrossRef: 147] [Cited by in F6Publishing: 154] [Article Influence: 9.8] [Reference Citation Analysis]
628 Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, Wakabayashi K, Ansari AA, Flavell RA, Ridgway WM, Coppel RL, Tsuneyama K, Mackay IR, Gershwin ME. Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 2008;47:1974-82. [PMID: 18452147 DOI: 10.1002/hep.22226] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
629 Chaparro M, Moreno-monteagudo J, Garca-buey L, Moreno-otero R. Enfermedades colest?sicas cr?nicas. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2008;10:777-783. [DOI: 10.1016/s0211-3449(08)73154-0] [Reference Citation Analysis]
630 Liu B, Zhang FC, Zhang ZL, Zhang W, Gao LX. Interstitial lung disease and Sjögren’s syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol. 2008;27:1299-1306. [PMID: 18512115 DOI: 10.1007/s10067-008-0917-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
631 Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, Oude Elferink RP, Prieto J, Medina JF. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008;134:1482-93. [PMID: 18471521 DOI: 10.1053/j.gastro.2008.02.020] [Cited by in Crossref: 149] [Cited by in F6Publishing: 160] [Article Influence: 9.9] [Reference Citation Analysis]
632 Juran BD, Lazaridis KN. Genetics and genomics of primary biliary cirrhosis. Clin Liver Dis 2008;12:349-65; ix. [PMID: 18456185 DOI: 10.1016/j.cld.2008.02.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
633 Silveira MG, Lindor KD. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis 2008;12:425-43; x-xi. [PMID: 18456189 DOI: 10.1016/j.cld.2008.02.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
634 Mendes FD, Kim WR, Pedersen R, Therneau T, Lindor KD. Mortality attributable to cholestatic liver disease in the United States. Hepatology 2008;47:1241-7. [PMID: 18318437 DOI: 10.1002/hep.22178] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
635 Wong GL, Law FM, Wong VW, Hui AY, Chan FK, Sung JJ, Chan HL. Health-related quality of life in Chinese patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2008;23:592-8. [PMID: 17645470 DOI: 10.1111/j.1440-1746.2007.05092.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
636 Eric Gershwin M, Selmi C, He X, Bowlus C. Relationship between Primary Biliary Cirrhosis and Lipoic Acid. Oxidative Stress and Disease 2008. [DOI: 10.1201/9781420045390.ch16] [Reference Citation Analysis]
637 Gómez-Dominguez E, Mendoza J, García-Buey L, Trapero M, Gisbert JP, Jones EA, Moreno-Otero R. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther 2008;27:441-7. [PMID: 18081731 DOI: 10.1111/j.1365-2036.2007.03585.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
638 Shimoda S, Harada K, Niiro H, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y, Tsuneyama K, Nakamura M, Komori A, Migita K, Nakanuma Y, Ishibashi H, Selmi C, Gershwin ME. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology 2008;47:958-65. [PMID: 18181218 DOI: 10.1002/hep.22102] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
639 Newton JL, Pairman J, Sutcliffe K, Wilton K, Jones DE. A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2008;6:228-33. [PMID: 18237872 DOI: 10.1016/j.cgh.2007.11.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
640 Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 2008;47:737-45. [PMID: 18098322 DOI: 10.1002/hep.22042] [Cited by in Crossref: 211] [Cited by in F6Publishing: 200] [Article Influence: 14.1] [Reference Citation Analysis]
641 Juran BD, Atkinson EJ, Schlicht EM, Fridley BL, Petersen GM, Lazaridis KN. Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology 2008;47:563-70. [PMID: 18041714 DOI: 10.1002/hep.22048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
642 Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int 2008;28:233-9. [PMID: 18251980 DOI: 10.1111/j.1478-3231.2007.01651.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
643 Paumgartner G, Pusl T. Medical treatment of cholestatic liver disease. Clin Liver Dis 2008;12:53-80, viii. [PMID: 18242497 DOI: 10.1016/j.cld.2007.11.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
644 Zollner G, Trauner M. Mechanisms of cholestasis. Clin Liver Dis 2008;12:1-26, vii. [PMID: 18242495 DOI: 10.1016/j.cld.2007.11.010] [Cited by in Crossref: 135] [Cited by in F6Publishing: 135] [Article Influence: 9.0] [Reference Citation Analysis]
645 Chuang YH, Lian ZX, Yang GX, Shu SA, Moritoki Y, Ridgway WM, Ansari AA, Kronenberg M, Flavell RA, Gao B, Gershwin ME. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 2008;47:571-80. [PMID: 18098320 DOI: 10.1002/hep.22052] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 5.8] [Reference Citation Analysis]
646 Sakauchi F, Oura A, Ohnishi H, Mori M. Comparison of the clinical features of Japanese patients with primary biliary cirrhosis in 1999 and 2004: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol. 2007;17:210-214. [PMID: 18094520 DOI: 10.2188/jea.17.210] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
647 Hu CJ, Li YZ, Zhao GF, Li N, Xu Y, Tong DW, Zhang SL. Screening for specific biomarkers in serum for diagnosis of primary biliary cirrhosis using proteomic fingerprint technology. Shijie Huaren Xiaohua Zazhi 2008; 16(3): 277-283 [DOI: 10.11569/wcjd.v16.i3.277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
648 Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1. [PMID: 18215315 DOI: 10.1186/1750-1172-3-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 88] [Article Influence: 4.9] [Reference Citation Analysis]
649 GRANULOMATOUS LIVER DISEASE. Gastroenterology and Hepatology 2008. [DOI: 10.1016/b978-0-7295-3775-9.50043-3] [Reference Citation Analysis]
650 Palau A, Berenguer J. Hepatopatías colestásicas del adulto. Trasplante hepático 2008. [DOI: 10.1016/b978-84-8086-310-0.50034-8] [Reference Citation Analysis]
651 Wang F, Gao GF. Regulatory T Cells in Hepatitis and Hepatocellular Carcinoma. Regulatory T Cells and Clinical Application 2008. [DOI: 10.1007/978-0-387-77909-6_21] [Reference Citation Analysis]
652 Sipe WE, Snyder JD. Chronic Hepatitis. Principles and Practice of Pediatric Infectious Disease 2008. [DOI: 10.1016/b978-0-7020-3468-8.50071-7] [Reference Citation Analysis]
653 Abdalian R, Heathcote J. Chapter 12 Primary Biliary Cirrhosis. Handbook of Systemic Autoimmune Diseases 2008. [DOI: 10.1016/s1571-5078(07)00012-8] [Reference Citation Analysis]
654 Clark VC, Levy C. Primary Biliary Cirrhosis. Cholestatic Liver Disease 2008. [DOI: 10.1007/978-1-59745-118-5_3] [Reference Citation Analysis]
655 Bennett PN, Brown MJ. Liver, biliary tract, pancreas. Clinical Pharmacology 2008. [DOI: 10.1016/b978-0-443-10244-8.10033-3] [Reference Citation Analysis]
656 Denk GU, Beuers U, Bogner JR, Fischereder M. Predisposing Diseases. Screening and Preventive Diagnosis with Radiological Imaging 2008. [DOI: 10.1007/978-3-540-49831-5_16] [Reference Citation Analysis]
657 Meyboom R. Metal antagonists. Side Effects of Drugs Annual 2008. [DOI: 10.1016/s0378-6080(08)00023-8] [Reference Citation Analysis]
658 Spadaro A, Scrivo R, Riccieri V, Valesini G. Effet des anti-TNF chez un patient ayant une polyarthite rhumatoïde et une cirrhose biliaire primitive. Revue du Rhumatisme 2008;75:91-93. [DOI: 10.1016/j.rhum.2007.03.011] [Reference Citation Analysis]
659 Smith AD. Overlap Syndromes with Autoimmune Hepatitis. Cholestatic Liver Disease 2008. [DOI: 10.1007/978-1-59745-118-5_5] [Reference Citation Analysis]
660 Selmi C, Gershwin ME. Primary Biliary Cirrhosis. Diagnostic Criteria in Autoimmune Diseases 2008. [DOI: 10.1007/978-1-60327-285-8_55] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
661 Inselman LS. Pulmonary Manifestations of Systemic Disorders. Pediatric Respiratory Medicine 2008. [DOI: 10.1016/b978-032304048-8.50079-7] [Reference Citation Analysis]
662 CHOLESTASIS AND JAUNDICE. Gastroenterology and Hepatology 2008. [DOI: 10.1016/b978-0-7295-3775-9.50032-9] [Reference Citation Analysis]
663 de Almeida SF, de Sousa M. The unfolded protein response in hereditary haemochromatosis. J Cell Mol Med 2008;12:421-34. [PMID: 18053083 DOI: 10.1111/j.1582-4934.2007.00179.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
664 Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P, Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I; USA PBC Epidemiology Group. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology 2007;46:1836-43. [PMID: 18027862 DOI: 10.1002/hep.21953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
665 Zollner G, Fickert P, Trauner M. Cholestase. wkw education 2007;2:125-140. [DOI: 10.1007/s11812-007-0029-6] [Reference Citation Analysis]
666 Allina J, Stanca CM, Garber J, Hu B, Sautes-Fridman C, Bach N, Odin JA. Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun 2008;30:238-45. [PMID: 18023559 DOI: 10.1016/j.jaut.2007.10.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
667 Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007;5:1313-5. [PMID: 17900996 DOI: 10.1016/j.cgh.2007.07.015] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 6.8] [Reference Citation Analysis]
668 Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007;27:1226-31. [PMID: 17919234 DOI: 10.1111/j.1478-3231.2007.01586.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 3.0] [Reference Citation Analysis]
669 Rautiainen H, Salomaa V, Niemelå S, Karvonen AL, Nurmi H, Isoniemi H, Färkkilä M. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol 2007;42:1347-53. [PMID: 17918011 DOI: 10.1080/00365520701396034] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 3.3] [Reference Citation Analysis]
670 Jones DE. Pathogenesis of primary biliary cirrhosis. Gut 2007;56:1615-24. [PMID: 17641080 DOI: 10.1136/gut.2007.122150] [Cited by in Crossref: 19] [Cited by in F6Publishing: 41] [Article Influence: 1.2] [Reference Citation Analysis]
671 Yamagiwa S, Ichida T. Recurrence of primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation in Japan. Hepatol Res 2007;37 Suppl 3:S449-54. [PMID: 17931201 DOI: 10.1111/j.1872-034X.2007.00250.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
672 Murdaca G, Colombo BM, Sprecacenere B, Caiti M, Massa G, Picciotto A, Ceppa P, Puppo F. Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome. Eur J Gastroenterol Hepatol 2007;19:910-2. [PMID: 17873618 DOI: 10.1097/MEG.0b013e32820a0035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
673 Corpechot C, Poupon R. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology 2007;46:963-5. [PMID: 17894325 DOI: 10.1002/hep.21871] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
674 Pla X, Vergara M, Gil M, Dalmau B, Cisteró B, Bella RM, Real J. Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol 2007;19:859-64. [PMID: 17873609 DOI: 10.1097/MEG.0b013e328277594a] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
675 Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Ferri S, Quarneti C, Cipriano V, de Molo C, Lenzi M, Chapman RW, Bianchi FB. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007;26:831-8. [PMID: 17767467 DOI: 10.1111/j.1365-2036.2007.03433.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
676 Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, Ghosh K, Dickson ER, Lindor KD, Petersen GM. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007;46:785-92. [PMID: 17680647 DOI: 10.1002/hep.21749] [Cited by in Crossref: 103] [Cited by in F6Publishing: 87] [Article Influence: 6.4] [Reference Citation Analysis]
677 Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, März W, Trauner M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007;46:776-84. [PMID: 17668874 DOI: 10.1002/hep.21741] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
678 Honda Y, Yamagiwa S, Matsuda Y, Takamura M, Ichida T, Aoyagi Y. Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol 2007;47:404-11. [PMID: 17448566 DOI: 10.1016/j.jhep.2007.03.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
679 Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007;102:1799-807. [PMID: 17459023 DOI: 10.1111/j.1572-0241.2007.01235.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 6.3] [Reference Citation Analysis]
680 Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, Zuin M, Gershwin ME, Podda M, Invernizzi P. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007;46:456-62. [PMID: 17659578 DOI: 10.1002/hep.21696] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 6.5] [Reference Citation Analysis]
681 Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007;46:463-71. [PMID: 17634963 DOI: 10.1002/hep.21700] [Cited by in Crossref: 202] [Cited by in F6Publishing: 172] [Article Influence: 12.6] [Reference Citation Analysis]
682 Taffetani S, Glaser S, Francis H, DeMorrow S, Ueno Y, Alvaro D, Marucci L, Marzioni M, Fava G, Venter J, Vaculin S, Vaculin B, Lam IP, Lee VH, Gaudio E, Carpino G, Benedetti A, Alpini G. Prolactin stimulates the proliferation of normal female cholangiocytes by differential regulation of Ca2+-dependent PKC isoforms. BMC Physiol 2007;7:6. [PMID: 17640386 DOI: 10.1186/1472-6793-7-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
683 Marzioni M, Svegliati Baroni G, Alpini G, Benedetti A. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 2007;46:583-6. [PMID: 17313989 DOI: 10.1016/j.jhep.2007.01.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
684 Robertson H, Kirby JA, Yip WW, Jones DE, Burt AD. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 2007;45:977-81. [PMID: 17393507 DOI: 10.1002/hep.21624] [Cited by in Crossref: 122] [Cited by in F6Publishing: 109] [Article Influence: 7.6] [Reference Citation Analysis]
685 Rieger R, Gershwin ME. The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 2007;28:76-84. [PMID: 17360156 DOI: 10.1016/j.jaut.2007.02.003] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 5.3] [Reference Citation Analysis]
686 Yang WH, Bloch DB. Probing the mRNA processing body using protein macroarrays and "autoantigenomics". RNA 2007;13:704-12. [PMID: 17339575 DOI: 10.1261/rna.411907] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 4.3] [Reference Citation Analysis]
687 Gur C, Lalazar G, Doviner V, Fridlender ZG, Molcho V, Abu-Much S, Shalit M, Elinav E. Late-onset sarcoidosis after liver transplantation for primary biliary cirrhosis. J Clin Gastroenterol 2007;41:329-32. [PMID: 17426476 DOI: 10.1097/01.mcg.0000212653.51397.f6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
688 Ueno Y, Moritoki Y, Shimosegawa T, Gershwin ME. Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models. J Gastroenterol 2007;42:189-95. [PMID: 17380276 DOI: 10.1007/s00535-007-2019-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
689 Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Gershwin ME. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007;45:659-65. [PMID: 17326160 DOI: 10.1002/hep.21583] [Cited by in Crossref: 116] [Cited by in F6Publishing: 109] [Article Influence: 7.3] [Reference Citation Analysis]
690 Tamura H, Okamoto M, Yamashita T, Sato C, Watanabe A, Kondo A, Tatsuguchi A, Tsuji T, Ogata K, Dan K. Pure white cell aplasia: report of the first case associated with primary biliary cirrhosis. Int J Hematol 2007;85:97-100. [PMID: 17321984 DOI: 10.1532/IJH97.06018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
691 Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25:471-6. [PMID: 17270003 DOI: 10.1111/j.1365-2036.2006.03223.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 5.4] [Reference Citation Analysis]
692 Oertelt S, Selmi C, Invernizzi P, Podda M, Coppel RL, Gershwin ME. Primary biliary cirrhosis and biliary destruction: 2005; a liver odyssey. Falk Symposium. [DOI: 10.1007/1-4020-4144-6_18] [Reference Citation Analysis]
693 Borum M, Entwisle C, Witte T. The Cirrhotic Patient. Trauma 2007. [DOI: 10.1201/b16040-81] [Reference Citation Analysis]
694 Uppal H, Saini SP, Moschetta A, Mu Y, Zhou J, Gong H, Zhai Y, Ren S, Michalopoulos GK, Mangelsdorf DJ, Xie W. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 2007;45:422-32. [PMID: 17256725 DOI: 10.1002/hep.21494] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 6.3] [Reference Citation Analysis]
695 Jones DE. Complications of cholestasis. Medicine 2007;35:96-8. [DOI: 10.1016/j.mpmed.2006.11.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
696 Allocca M, Crosignani A, Gritti A, Benetti A, Zuin M, Podda M, Battezzati PM. Inadequate dietary intake but not renal tubular acidosis is associated with bone demineralization in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25:219-27. [PMID: 17229245 DOI: 10.1111/j.1365-2036.2006.03181.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
697 Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, van de Water J, LaRusso NF, Gershwin ME, Gores GJ, Odin JA. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006;27:232-41. [PMID: 17222534 DOI: 10.1016/j.jaut.2006.11.004] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 4.5] [Reference Citation Analysis]
698 Selected Organ System Abnormalities. Practical Guide to the Care of the Geriatric Patient 2007. [DOI: 10.1016/b978-0-323-03671-9.50012-5] [Reference Citation Analysis]
699 Retana AK, Kaplan MM, Erban JK. Autoimmune hemolytic anemia in patients with liver transplants for primary biliary cirrhosis: Three case reports and a review of the literature. Am J Gastroenterol 2007;102:197-200. [PMID: 17037996 DOI: 10.1111/j.1572-0241.2006.00810.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
700 Ishibashi H. Anti-mitochondrial antibodies in collagen diseases and the association of primary biliary cirrhosis. Kanzo 2007;48:204-206. [DOI: 10.2957/kanzo.48.204] [Reference Citation Analysis]
701 Pusl T, Denk GU, Parhofer KG, Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006;45:887-91. [PMID: 17046095 DOI: 10.1016/j.jhep.2006.08.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
702 Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, DE Molo C, Lenzi M, Chapman RW, Bianchi FB. Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther 2006;24:1575-83. [PMID: 17206945 DOI: 10.1111/j.1365-2036.2006.03172.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
703 Pausch J, Gatzen M. [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?]. Internist (Berl) 2006;47:1239-40, 1242-4. [PMID: 17077981 DOI: 10.1007/s00108-006-1732-6] [Reference Citation Analysis]
704 Wakabayashi K, Lian ZX, Moritoki Y, Lan RY, Tsuneyama K, Chuang YH, Yang GX, Ridgway W, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Gershwin ME. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006;44:1240-9. [PMID: 17058261 DOI: 10.1002/hep.21385] [Cited by in Crossref: 182] [Cited by in F6Publishing: 171] [Article Influence: 10.7] [Reference Citation Analysis]
705 Marangoni A, Donati M, Cavrini F, Aldini R, Accardo S, Sambri V, Montagnani M, Cevenini R. Chlamydia pneumoniae replicates in Kupffer cells in mouse model of liver infection. World J Gastroenterol 2006; 12(40): 6453-6457 [PMID: 17072977 DOI: 10.3748/wjg.v12.i40.6453] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
706 Bellucci R, Oertelt S, Gallagher M, Li S, Zorn E, Weller E, Porcheray F, Alyea EP, Soiffer RJ, Munshi NC, Gershwin ME, Ritz J. Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood 2007;109:2001-7. [PMID: 17068145 DOI: 10.1182/blood-2006-06-030304] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
707 Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137-1140. [PMID: 16931765 DOI: 10.1126/science.1128294] [Cited by in Crossref: 1838] [Cited by in F6Publishing: 1904] [Article Influence: 108.1] [Reference Citation Analysis]
708 Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther 2006;24:813-20. [PMID: 16918885 DOI: 10.1111/j.1365-2036.2006.03048.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
709 Watanabe N, Takashimizu S, Shiraishi K, Kagawa T, Nishizaki Y, Mine T, Akatsuka A, Selmi C, Gershwin ME. Primary biliary cirrhosis with multinucleated hepatocellular giant cells: implications for pathogenesis of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2006;18:1023-7. [PMID: 16894319 DOI: 10.1097/01.meg.0000230082.60921.be] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
710 Bogdanos DP, Vergani D. Origin of cross-reactive autoimmunity in primary biliary cirrhosis. Liver Int 2006;26:633-5. [PMID: 16842317 DOI: 10.1111/j.1478-3231.2006.01291.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
711 Lazzaro A, Bernuzzi P, Arcari A, Bertè R, Moroni FC, Trabacchi E, Vallisa D, Cavanna L. A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy. Am J Hematol 2006;81:557. [PMID: 16755555 DOI: 10.1002/ajh.20586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
712 Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:1529-38. [PMID: 16863557 DOI: 10.1111/j.1572-0241.2006.00634.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 5.1] [Reference Citation Analysis]
713 Alvaro D, Mancino MG, Onori P, Franchitto A, Alpini G, Francis H, Glaser S, Gaudio E. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 2006; 12(22): 3537-3545 [PMID: 16773710 DOI: 10.3748/wjg.v12.i22.3537] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 100] [Article Influence: 5.6] [Reference Citation Analysis]
714 Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135-44. [PMID: 16628641 DOI: 10.1002/hep.21172] [Cited by in Crossref: 137] [Cited by in F6Publishing: 124] [Article Influence: 8.1] [Reference Citation Analysis]
715 Lefkowitch JH. Hepatobiliary pathology. Curr Opin Gastroenterol 2006;22:198-208. [PMID: 16550033 DOI: 10.1097/01.mog.0000218955.55688.af] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
716 Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y, Chuang YH, Nakamura T, Saito S, Shimoda S, Tanaka A, Bowlus CL, Takano Y, Ansari AA, Coppel RL, Gershwin ME. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006;43:729-37. [PMID: 16557534 DOI: 10.1002/hep.21123] [Cited by in Crossref: 236] [Cited by in F6Publishing: 224] [Article Influence: 13.9] [Reference Citation Analysis]
717 Koulentaki M, Ioannidou D, Stefanidou M, Maraki S, Drigiannakis I, Dimoulios P, Melono JM, Tosca A, Kouroumalis EA. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006;101:541-6. [PMID: 16464228 DOI: 10.1111/j.1572-0241.2006.00423.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
718 医学と医療の最前線  自己免疫性肝疾患とその周辺疾患―その発症要因は何か?. J Jpn Soc Intern Med 2006;95:756-762. [DOI: 10.2169/naika.95.756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
719 Primary Biliary Cirrhosis. N Engl J Med 2005;353:2719-2720. [DOI: 10.1056/nejmc052817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]